{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:31:26Z","timestamp":1790303486719,"version":"4.1.0"},"reference-count":294,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T00:00:00Z","timestamp":1570147200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T00:00:00Z","timestamp":1570147200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Neurobiol"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s10571-019-00741-0","type":"journal-article","created":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T09:04:59Z","timestamp":1570179899000},"page":"313-345","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Elucidating Critical Proteinopathic Mechanisms and Potential Drug Targets in Neurodegeneration"],"prefix":"10.1007","volume":"40","author":[{"given":"Khalid Bashir","family":"Dar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aashiq Hussain","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shajrul","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilal Ahmad","family":"Reshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Afzal","family":"Zargar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akbar","family":"Masood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6295-4959","authenticated-orcid":false,"given":"Showkat Ahmad","family":"Ganie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,4]]},"reference":[{"key":"741_CR1","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/cbdd.12056","volume":"81","author":"PA Abreu","year":"2013","unstructured":"Abreu PA, Castro HC, Paes-de-Carvalho R et al (2013) Molecular modeling of a phenylamidine class of NMDA receptor antagonists and the rational design of new triazolyl-amidine derivatives. Chem Biol Drug Des 81:185\u2013197","journal-title":"Chem Biol Drug Des"},{"key":"741_CR2","doi-asserted-by":"crossref","first-page":"9677","DOI":"10.1523\/JNEUROSCI.4742-11.2012","volume":"32","author":"O Adolfsson","year":"2012","unstructured":"Adolfsson O, Pihlgren M, Toni N, Varisco Y, Buccarello AL, Antoniello K, Lohmann S, Piorkowska K, Gafner V, Atwal JK, Maloney J (2012) An effector- reduced anti- \u03b2-amyloid (A\u03b2) antibody with unique A\u03b2 binding properties promotes neuroprotection and glial engulfment of A\u03b2. J Neurosci 32:9677\u20139789","journal-title":"J Neurosci"},{"key":"741_CR3","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3389\/fmolb.2015.00054","volume":"2","author":"M Agrawal","year":"2015","unstructured":"Agrawal M, Biswas A (2015) Molecular diagnostics of neurodegenerative disorders. Front Mol Biosci 2:54","journal-title":"Front Mol Biosci"},{"key":"741_CR4","doi-asserted-by":"crossref","first-page":"R110006924","DOI":"10.1074\/mcp.M110.006924","volume":"10","author":"CT Aiken","year":"2011","unstructured":"Aiken CT, Kaake RM, Wang X, Huang L (2011) Oxidative stress-mediated regulation of proteasome complexes. Mol Cell Proteom 10:R110006924","journal-title":"Mol Cell Proteom"},{"key":"741_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/3087475","volume":"2018","author":"F Alasmari","year":"2018","unstructured":"Alasmari F, Alshammari MA, Alasmari AF, Alanazi WA, Alhazzani K (2018) Neuroinflammatory cytokines induce amyloid beta neurotoxicity through modulating amyloid precursor protein levels\/metabolism. Biomed Res Int 2018:1\u20138","journal-title":"Biomed Res Int"},{"key":"741_CR6","doi-asserted-by":"crossref","first-page":"37967","DOI":"10.1074\/jbc.M105365200","volume":"276","author":"ADC Alonso","year":"2001","unstructured":"Alonso ADC, Zaidi T, Novak M, Barra HS, Grundke-Iqbal I, Iqbal K (2001) Interaction of tau isoforms with Alzheimer\u2019s disease abnormally hyperphosphorylated tau and in vitro phosphorylation into the disease-like protein. J Biol Chem 276:37967\u201337973","journal-title":"J Biol Chem"},{"key":"741_CR7","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.nbd.2014.11.018","volume":"81","author":"A Anandhan","year":"2015","unstructured":"Anandhan A, Rodriguez-Rocha H, Bohovych I et al (2015) Overexpression of alpha-synuclein at non-toxic levels increases dopaminergic cell death induced by copper exposure via modulation of protein degradation pathways. Neurobiol Dis 81:76\u201392","journal-title":"Neurobiol Dis"},{"issue":"2","key":"741_CR8","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.neulet.2011.09.026","volume":"504","author":"TA Ansah","year":"2011","unstructured":"Ansah TA, Ferguson MC, Nayyar T, Deutch AY (2011) Age and durationdependent effects of MPTP on cortical serotonin systems. Neurosci Lett 504(2):160\u2013164","journal-title":"Neurosci Lett"},{"key":"741_CR9","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0006-8993(99)01848-X","volume":"843","author":"K Arima","year":"1999","unstructured":"Arima K, Hirai S, Sunohara N et al (1999) Cellular co-localization of phosphorylated tau-and NACP\/\u03b1-synuclein-epitopes in lewy bodies in sporadic Parkinson\u2019s disease and in dementia with lewy bodies. Brain Res 843:53\u201361","journal-title":"Brain Res"},{"key":"741_CR10","doi-asserted-by":"crossref","first-page":"6412","DOI":"10.1038\/s41598-018-24501-0","volume":"8","author":"JW Arndt","year":"2018","unstructured":"Arndt JW, Qian F, Smith BA, Quan C, Kilambi KP, Bush MW, Walz T, Pepinsky RB, Bussi\u00e8re T, Hamann S, Cameron TO (2018) Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid- \u03b2. Sci Rep 8:6412","journal-title":"Sci Rep"},{"key":"741_CR11","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/0968-0004(92)90011-W","volume":"17","author":"Y Asaoka","year":"1992","unstructured":"Asaoka Y, Nakamura S, Yoshida K, Nishizuka Y (1992) Protein kinase C calcium and phospholipi degradation. Trends Biochem 17:414\u2013417","journal-title":"Trends Biochem"},{"key":"741_CR12","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1126\/science.1067389","volume":"295","author":"PK Auluck","year":"2002","unstructured":"Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM (2002) Chaperone suppression of alpha-synuclein toxicity in a drosophila model for Parkinson\u2019s disease. Science 295:865\u2013868","journal-title":"Science"},{"issue":"8","key":"741_CR13","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.febslet.2010.03.012","volume":"584","author":"K Banerjee","year":"2010","unstructured":"Banerjee K, Sinha M, Pham CLL et al (2010) Alpha-synuclein induced membrane depolarization and loss of phosphorylation capacity of isolated rat brain mitochondria: implications in Parkinson\u2019s disease. FEBS Lett 584(8):1571\u20131576","journal-title":"FEBS Lett"},{"key":"741_CR14","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1212\/01.WNL.0000073136.00548.D4","volume":"61","author":"W Bara-Jimenez","year":"2003","unstructured":"Bara-Jimenez W, Sherzai A, Dimitrova T, Favit A, Bibbiani F, Gillespie M, Morris JM, Mouradian MM, Chase TN (2003) Adenosine A2A receptor antagonist treatment of Parkinson\u2019s disease. Neurology 61:293\u2013296","journal-title":"Neurology"},{"key":"741_CR15","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.3233\/JAD-150962","volume":"51","author":"NR Barth\u00e9lemy","year":"2016","unstructured":"Barth\u00e9lemy NR, Gabelle A, Hirtz C, Fenaille F, Sergeant N, Schraen-Maschke S, Vialaret J, Bu\u00e9e L, Junot C, Becher F, Lehmann S (2016) Differential mass spectrometry profiles of tau protein in the cerebrospinal fluid of patients with Alzheimer\u2019s disease, progressive supranuclear palsy, and dementia with lewy bodies. J Alzheimers Dis 51:1033\u20131043","journal-title":"J Alzheimers Dis"},{"key":"741_CR16","volume-title":"Basic neurochemistry","author":"NG Bazan","year":"1999","unstructured":"Bazan NG (1999) Eicosanoids, platelet-activating factor and inflammation. In: Siegel GJ, Agranoff BW, Albers RW, Fisher SK, Uhler MD (eds) Basic neurochemistry. Raven Press Ltd, New York"},{"key":"741_CR17","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1074\/jbc.M804755200","volume":"284","author":"SA Bellingham","year":"2009","unstructured":"Bellingham SA, Coleman LA, Masters CL, Ca-makaris J, Hill AF (2009) Regulation of prion gene expression by transcription factors SP1 and metal transcription factor-1. J Biol Chem 284:1291\u20131301","journal-title":"J Biol Chem"},{"issue":"2","key":"741_CR18","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.tips.2006.12.005","volume":"28","author":"MM Bespalov","year":"2007","unstructured":"Bespalov MM, Saarma M (2007) GDNF family receptor complexes are emerging drug targets. Trends Pharm Sci 28(2):68\u201374","journal-title":"Trends Pharm Sci"},{"key":"741_CR19","first-page":"061820","volume":"1","author":"MM Bespalov","year":"2016","unstructured":"Bespalov MM, Sidorova YA, Suleymanova I et al (2016) Novel agonist of GDNF family ligand receptor RET for the treatment of experimental neuropathy. BioRxiv 1:061820","journal-title":"BioRxiv"},{"key":"741_CR20","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.biopha.2015.07.025","volume":"74","author":"AH Bhat","year":"2015","unstructured":"Bhat AH, Dar KB, Anees S, Zargar MA, Masood A, Sofi MA, Ganie SA (2015) Oxidative stress, mitochondrial dysfunction and neurodegenerative diseases, a mechanistic insight. Biomed Pharmacother 74:101\u2013110","journal-title":"Biomed Pharmacother"},{"key":"741_CR22","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/nature13418","volume":"510","author":"B Bingol","year":"2014","unstructured":"Bingol B, Tea JS, Phu L, Reichelt M, Bakalarski CE, Song Q (2014) The mitochondrial deubiquitinase USP30 opposes parkin-mediated mitophagy. Nature 510:370\u2013375","journal-title":"Nature"},{"key":"741_CR23","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/jnc.12966","volume":"131","author":"A Bir","year":"2014","unstructured":"Bir A, Sen O, Anand S et al (2014) \u03b1-Synuclein-induced mitochondrial dysfunction in isolated preparation and intact cells: implications in the pathogenesis of Parkinson\u2019s disease. J Neurochem 131:868\u2013877","journal-title":"J Neurochem"},{"key":"741_CR24","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3233\/JAD-2011-110977","volume":"28","author":"B Bohrmann","year":"2012","unstructured":"Bohrmann B, Baumann K, Benz J et al (2012) Gantenerumab: a novel human anti- A\u03b2 antibody demonstrates sustained cerebral amyloid- \u03b2 binding and elicits cell- mediated removal of human amyloid- \u03b2. J Alzheimers Dis 28:49\u201369","journal-title":"J Alzheimers Dis"},{"key":"741_CR25","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1111\/j.1582-4934.2011.01318.x","volume":"15","author":"D Bosco","year":"2011","unstructured":"Bosco D, Fava A, Plastino M, Montalcini T, Pujia A (2011) Possible implications of insulin resistance and glucose metabolism in Alzheimer\u2019s disease pathogenesis. J Cell Mol Med 15:1807\u20131821","journal-title":"J Cell Mol Med"},{"key":"741_CR26","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00401-015-1489-x","volume":"130","author":"Y Bouter","year":"2015","unstructured":"Bouter Y, Noguerola JS, Tucholla P, Crespi GA, Parker MW, Wiltfang J, Miles LA, Bayer TA (2015) A\u03b2 targets of the biosimilar antibodies of bapineuzumab, crenezumab, solanezumab in comparison to an antibody against N- truncated A\u03b2 in sporadic Alzheimer disease cases and mouse models. Acta Neuropathol 130:713\u2013729","journal-title":"Acta Neuropathol"},{"issue":"34","key":"741_CR27","doi-asserted-by":"crossref","first-page":"23679","DOI":"10.1074\/jbc.274.34.23679","volume":"274","author":"AR Brash","year":"1999","unstructured":"Brash AR (1999) Lipoxygenases: occurrence, functions, catalysis, and acquisition of substrate. J Biol Chem 274(34):23679\u201323682","journal-title":"J Biol Chem"},{"issue":"2","key":"741_CR28","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.freeradbiomed.2008.04.006","volume":"45","author":"MW Brazier","year":"2008","unstructured":"Brazier MW, Doctrow SR, Masters CL, Collins SJ (2008) A manganese-superoxide dismutase\/catalase mimetic extends survival in a mouse model of human prion disease. Free Radic Biol Med 45(2):184\u2013192","journal-title":"Free Radic Biol Med"},{"key":"741_CR29","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1002\/prot.23152","volume":"79","author":"IB Bruinsma","year":"2011","unstructured":"Bruinsma IB, Bruggink KA, Kinast K (2011) Inhibition of alpha-synuclein aggregation by small heat shock proteins. Proteins 79:2956\u20132967","journal-title":"Proteins"},{"issue":"3","key":"741_CR30","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1039\/C4MT00339J","volume":"7","author":"E Carboni","year":"2015","unstructured":"Carboni E, Lingor P (2015) Insights on the interaction of alpha-synuclein and metals in the pathophysiology of Parkinson\u2019s disease. Metallomics 7(3):395\u2013404","journal-title":"Metallomics"},{"key":"741_CR31","first-page":"279","volume":"50","author":"MP Caulfield","year":"1998","unstructured":"Caulfield MP, Bridsall NJ (1998) International Union of Pharmacology XVII classification of muscarinic acetylcholine receptors. Pharmacol Rev 50:279\u2013290","journal-title":"Pharmacol Rev"},{"issue":"4","key":"741_CR32","doi-asserted-by":"crossref","first-page":"282","DOI":"10.14336\/AD.2014.002","volume":"6","author":"S Chakrabarti","year":"2015","unstructured":"Chakrabarti S, Khemka VK, Banerjee A, Chatterjee G, Ganguly A, Biswas A (2015) Metabolic risk factors of sporadic Alzheimer\u2019s disease: implications in the pathology, pathogenesis and treatment. Aging Dis 6(4):282\u2013299","journal-title":"Aging Dis"},{"issue":"6","key":"741_CR33","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1080\/14728222.2017.1323881","volume":"21","author":"SL Chan","year":"2017","unstructured":"Chan SL, Tan EK (2017) Targeting LRRK2 in Parkinson\u2019s disease: an update on recent developments. Expert Opin Ther Targets 21(6):601\u2013610","journal-title":"Expert Opin Ther Targets"},{"key":"741_CR34","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/mds.25835","volume":"29","author":"A Chandra","year":"2014","unstructured":"Chandra A, Johri A, Beal MF (2014) Prospects for neuroprotective therapies in prodromal Huntington\u2019s disease. Mov Disord 29:285\u2013293","journal-title":"Mov Disord"},{"key":"741_CR35","doi-asserted-by":"crossref","first-page":"RC143","DOI":"10.1523\/JNEUROSCI.21-10-j0001.2001","volume":"21","author":"JF Chen","year":"2001","unstructured":"Chen JF, Xu K, Petzer JP et al (2001) Neuroprotection by caffeine and A2A adenosine receptor inactivation in a model of Parkinson\u2019s disease. J Neurosci 21:RC143","journal-title":"J Neurosci"},{"key":"741_CR36","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1074\/jbc.M609388200","volume":"282","author":"S Cho","year":"2007","unstructured":"Cho S, Szeto HH, Kim E, Kim H, Tolhurst AT, Pinto JT (2007) A novel cell-permeable antioxidant peptide, SS31, attenuates ischemic brain injury by down-regulating CD36. J Biol Chem 282:4634\u20134642","journal-title":"J Biol Chem"},{"key":"741_CR37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12017-009-8104-z","volume":"121","author":"VW Chow","year":"2010","unstructured":"Chow VW, Mattson MP, Wong PC, Gleichmann M (2010) An overview of APP processing enzymes and products. NeuroMol Med 121:1\u201312","journal-title":"NeuroMol Med"},{"key":"741_CR38","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1098\/rstb.2000.0764","volume":"356","author":"AR Clarke","year":"2001","unstructured":"Clarke AR, Jackson GS, Collinge J (2001) The molecular biology of prion propagation. Philos Trans R Soc Lond, Ser B 356:185\u2013195","journal-title":"Philos Trans R Soc Lond, Ser B"},{"key":"741_CR39","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s10863-009-9242-6","volume":"41","author":"A Colell","year":"2009","unstructured":"Colell A, Fernandez A, Fernandez-Checa JC (2009) Mitochondria, cholesterol and amyloid \u03b2 peptide: a dangerous trio in Alzheimer disease. J Bioenerg Biomembr 41:417\u2013423","journal-title":"J Bioenerg Biomembr"},{"key":"741_CR40","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.ejmech.2012.05.036","volume":"54","author":"V Colotta","year":"2012","unstructured":"Colotta V, Lenzi O, Catarzi D et al (2012) 3-Hydroxy-1H-quinazoline-2,4-dione derivatives as new antagonists at ionotropic glutamate receptors: molecular modeling and pharmacological studies. Eur J Med Chem 54:470\u2013482","journal-title":"Eur J Med Chem"},{"key":"741_CR41","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.3233\/JAD-132435","volume":"40","author":"EE Congdon","year":"2014","unstructured":"Congdon EE, Krishnaswamy S, Sigurdsson EM (2014) Harnessing the immune system for treatment and detection of tau pathology. J Alzheimers Dis 40:S113\u2013S121","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"741_CR42","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0002-9440(10)64354-4","volume":"160","author":"IS Coraci","year":"2002","unstructured":"Coraci IS, Husemann J, Berman JW et al (2002) CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer\u2019s disease brains and can mediate production of reactive oxygen species in response to beta-amyloid fibrils. Am J Pathol 160(1):101\u2013112","journal-title":"Am J Pathol"},{"key":"741_CR43","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1001\/archneurol.2012.2194","volume":"69","author":"V Coric","year":"2012","unstructured":"Coric V, Van-Dyck CH, Salloway S, Andreasen N, Brody M, Richter RW et al (2012) Safety and tolerability of the \u03b3-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol 69:1430\u20131440","journal-title":"Arch Neurol"},{"key":"741_CR44","first-page":"293","volume":"43","author":"J Cornelis","year":"2011","unstructured":"Cornelis J, Schyf VD (2011) the use of multi-target drugs in the treatment of neurodegenerative diseases. Exp Rev Clin Pharmacol 43:293\u2013298","journal-title":"Exp Rev Clin Pharmacol"},{"key":"741_CR45","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1093\/hmg\/ddu244","volume":"23","author":"T Cornelissen","year":"2014","unstructured":"Cornelissen T, Haddad D, Wauters F, Van-Humbeeck C, Mandemakers W, Koentjoro B (2014) The deubiquitinase USP15 antagonizes Parkin-mediated mitochondrial ubiquitination and mitophagy. Human Mol Genet 23:5227\u20135242","journal-title":"Human Mol Genet"},{"key":"741_CR46","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ceca.2011.02.004","volume":"49","author":"E Coussee","year":"2011","unstructured":"Coussee E, De-Smet P, Bogaert E, Coussee E, De-Smet P, Bogaert E, Elens I, Van-Damme P, Willems P, Koopman W, Van-Den-Bosch L, Callewaert G (2011) G37R SOD1 mutant alters mitochondrial complex I activity, Ca2+ uptake and ATP production. Cell Calcium 49:217\u2013225","journal-title":"Cell Calcium"},{"issue":"1823","key":"741_CR47","doi-asserted-by":"crossref","first-page":"20152397","DOI":"10.1098\/rspb.2015.2397","volume":"283","author":"P Cox","year":"2016","unstructured":"Cox P, Davis D, Mash D, Metcalf J, Banack S (2016) Dietary exposure to an environmental toxin triggers neurofibrillary tangles and amyloid deposits in the brain. Proc R Soc B 283(1823):20152397","journal-title":"Proc R Soc B"},{"key":"741_CR48","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/978-3-540-89615-9_3","volume":"193","author":"G Cristalli","year":"2009","unstructured":"Cristalli G, Muller CE, Volpini R (2009) Recent developments in adenosine A2A receptor ligands. Handb Exp Pharmacol 193:59\u201398","journal-title":"Handb Exp Pharmacol"},{"issue":"42","key":"741_CR49","doi-asserted-by":"crossref","first-page":"14465","DOI":"10.1523\/JNEUROSCI.2246-12.2012","volume":"32","author":"AC Crist\u00f3v\u00e3o","year":"2012","unstructured":"Crist\u00f3v\u00e3o AC, Guhathakurta S, Bok E et al (2012) NADPH oxidase 1 mediates \u03b1-synucleinopathy in Parkinson\u2019s disease. J Neurosci 32(42):14465\u201314477","journal-title":"J Neurosci"},{"key":"741_CR50","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1126\/science.1101738","volume":"305","author":"AM Cuervo","year":"2004","unstructured":"Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D (2004) Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305:1292\u20131295","journal-title":"Science"},{"key":"741_CR51","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3109\/10520290903389445","volume":"85","author":"MR D\u2019Andrea","year":"2010","unstructured":"D\u2019Andrea MR, Nagele RG (2010) Morphologically distinct types of amyloid plaques point the way to a better understanding of Alzheimer\u2019s disease pathogenesis. Biotech Histochem 85:133\u2013147","journal-title":"Biotech Histochem"},{"issue":"7","key":"741_CR52","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1021\/cn400086m","volume":"4","author":"BJ Davie","year":"2013","unstructured":"Davie BJ, Christopoulos A, Scammells PJ (2013) Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficits. ACS Chem Neurosci 4(7):1026\u20131048","journal-title":"ACS Chem Neurosci"},{"key":"741_CR53","doi-asserted-by":"crossref","first-page":"12535","DOI":"10.1523\/JNEUROSCI.1920-10.2010","volume":"30","author":"B Dehay","year":"2010","unstructured":"Dehay B, Bove J, Rodr\u00edguez-Muela N et al (2010) Pathogenic lysosomal depletion in Parkinson\u2019s disease. J Neurosci 30:12535\u201312544","journal-title":"J Neurosci"},{"key":"741_CR54","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1474-4422(15)00006-X","volume":"14","author":"B Dehay","year":"2015","unstructured":"Dehay B, Bourdenx M, Gorry P, Przedborski S, Vila M, Hunot S, Singleton A, Olanow CW, Merchant KM, Bezard E, Petsko GA (2015) Targeting \u03b1-synuclein for treatment of Parkinson\u2019s disease: mechanistic and therapeutic considerations. Lancet Neurol 14:855\u2013866","journal-title":"Lancet Neurol"},{"issue":"9","key":"741_CR55","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1021\/jm4011669","volume":"57","author":"M De-Lera-Ruiz","year":"2013","unstructured":"De-Lera-Ruiz M, Lim YH, Zheng J (2013) Adenosine A2A receptor as a drug discovery target. J Med Chem 57(9):3623\u20133650","journal-title":"J Med Chem"},{"key":"741_CR56","doi-asserted-by":"crossref","first-page":"8850","DOI":"10.1073\/pnas.151261398","volume":"98","author":"RB DeMattos","year":"2001","unstructured":"DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM (2001) Peripheral anti- A\u03b2 antibody alters CNS and plasma A\u03b2 clearance and decreases brain A\u03b2burden in a mouse model of Alzheimer\u2019s disease. Proc Natl Acad Sci USA 98:8850\u20138855","journal-title":"Proc Natl Acad Sci USA"},{"issue":"35","key":"741_CR57","doi-asserted-by":"crossref","first-page":"9057","DOI":"10.1523\/JNEUROSCI.1469-06.2006","volume":"26","author":"L Devi","year":"2006","unstructured":"Devi L, Prabhu BM, Galati DF, Avadhani NG, Anandatheerthavarada HK (2006) Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer\u2019s disease brain is associated with mitochondrial dysfunction. J Neurosci 26(35):9057\u20139068","journal-title":"J Neurosci"},{"key":"741_CR58","first-page":"1191","volume":"112","author":"TB De-Villemeur","year":"2013","unstructured":"De-Villemeur TB (2013) Creutzfeldt-Jakob disease Handbook of clinical neurology. Elsevier 112:1191\u20131193","journal-title":"Elsevier"},{"issue":"342","key":"741_CR59","doi-asserted-by":"crossref","first-page":"342ra78","DOI":"10.1126\/scitranslmed.aaf3634","volume":"8","author":"R Di-Maio","year":"2016","unstructured":"Di-Maio R, Barrett PJ, Hoffman EK et al (2016) \u03b1-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson\u2019s disease. Sci Transl Med 8(342):342ra78","journal-title":"Sci Transl Med"},{"key":"741_CR60","first-page":"7","volume":"51","author":"R Dingledine","year":"1999","unstructured":"Dingledine R, Borges K, Bowie D, Traynelis SF (1999) The glutamate receptor ion channels. Pharmacol Rev 51:7\u201361","journal-title":"Pharmacol Rev"},{"key":"741_CR61","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nn842","volume":"5","author":"JC Dodart","year":"2002","unstructured":"Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM (2002) Immunization reverses memory deficits without reducing brain A\u03b2 burden in Alzheimer\u2019s disease model. Nat Neurosci 5:452\u2013457","journal-title":"Nat Neurosci"},{"issue":"4","key":"741_CR62","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1212\/01.WNL.0000031424.51127.2B","volume":"60","author":"M Doder","year":"2003","unstructured":"Doder M, Rabiner EA, Turjanski N, Lees AJ, Brooks DJ (2003) Study CWP: tremor in Parkinson\u2019s disease and serotonergic dysfunction: an 11C-WAY 100635 PET study. Neurology 60(4):601\u2013605","journal-title":"Neurology"},{"key":"741_CR63","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1742-2094-11-48","volume":"11","author":"D Doens","year":"2014","unstructured":"Doens D, Fern\u00e1ndez PL (2014) Microglia receptors and their implications in the response to amyloid \u03b2 for Alzheimer\u2019s disease pathogenesis. J Neuroinflammation 11:48","journal-title":"J Neuroinflammation"},{"key":"741_CR64","doi-asserted-by":"crossref","first-page":"30797","DOI":"10.1074\/jbc.M505249200","volume":"280","author":"D Dominguez","year":"2005","unstructured":"Dominguez D, Tournoy J, Hartmann D, Huth T, Cryns K, Deforce S et al (2005) Phenotypic and biochemical analyses of BACE1-and BACE2-deficient mice. J Biol Chem 280:30797\u201330806","journal-title":"J Biol Chem"},{"key":"741_CR65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/cshperspect.a015008","volume":"5","author":"JE Dominy","year":"2013","unstructured":"Dominy JE, Puigserver P (2013) Mitochondrial biogenesis through activation of nuclear signaling proteins. Cold Spring Harb Perspect Biol 5:1\u201318","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"741_CR66","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1210951","volume":"369","author":"RS Doody","year":"2013","unstructured":"Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S et al (2013) A phase 3 trial of semagacestat for treatment of Alzheimer\u2019s disease. New Engl J Med 369:341\u2013350","journal-title":"New Engl J Med"},{"issue":"1","key":"741_CR68","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40035-018-0107-y","volume":"7","author":"X Du","year":"2018","unstructured":"Du X, Wang X, Geng M (2018) Alzheimer\u2019s disease hypothesis and related therapies. Transl Neuro 7(1):2. https:\/\/doi.org\/10.1186\/s40035-018-0107-y","journal-title":"Transl Neuro"},{"key":"741_CR69","doi-asserted-by":"crossref","first-page":"e201489729","DOI":"10.15252\/embj.201489729","volume":"33","author":"TM Durcan","year":"2014","unstructured":"Durcan TM, Tang MY, P\u00e9russe JR et al (2014) USP8 regulates mitophagy by removing K6-linked ubiquitin conjugates from parkin. EMBO J 33:e201489729","journal-title":"EMBO J"},{"key":"741_CR70","doi-asserted-by":"crossref","first-page":"14508","DOI":"10.1523\/JNEUROSCI.1560-11.2011","volume":"3141","author":"D Ebrahimi-Fakhari","year":"2011","unstructured":"Ebrahimi-Fakhari D, Cantuti-Castelvetri I, Fan Z et al (2011) Distinct roles in vivo for the ubiquitin\u2013proteasome system and the autophagy-lysosomal pathway in the degradation of \u03b1-synuclein. J Neurosci 3141:14508\u201314520","journal-title":"J Neurosci"},{"key":"741_CR71","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/2051-5960-1-79","volume":"1","author":"D Ebrahimi-Fakhari","year":"2013","unstructured":"Ebrahimi-Fakhari D, Saidi LJ, Wahlster L (2013) Molecular chaperones and protein folding as therapeutic targets in Parkinson\u2019s disease and other synucleinopathies. Acta Neuropathol Commun 1:79. https:\/\/doi.org\/10.1186\/2051-5960-1-79","journal-title":"Acta Neuropathol Commun"},{"key":"741_CR72","doi-asserted-by":"crossref","first-page":"372","DOI":"10.4161\/auto.5604","volume":"4","author":"S Engelender","year":"2008","unstructured":"Engelender S (2008) Ubiquitination of alpha synuclein and autophagy in Parkinson\u2019s disease. Autophagy 4:372\u2013374","journal-title":"Autophagy"},{"key":"741_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0013-z","author":"E Erin","year":"2018","unstructured":"Erin E, Congdon Einar MS (2018) Tau-targeting therapies for Alzheimer disease. Neurology. https:\/\/doi.org\/10.1038\/s41582-018-0013-z","journal-title":"Neurology"},{"key":"741_CR74","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1747-0285.2012.01317.x","volume":"79","author":"M Espinoza-Moraga","year":"2012","unstructured":"Espinoza-Moraga M, Caballero J, Gaube F, Winckler T, Santos LS (2012) 1-Benzyl-1, 2, 3, 4-tetrahydro-b-carboline as channel blocker of N-methyl-D-aspartate receptors. Chem Biol Drug Des 79:594\u2013599","journal-title":"Chem Biol Drug Des"},{"key":"741_CR75","first-page":"4","volume":"8","author":"HSA Ezza","year":"2014","unstructured":"Ezza HSA, Khadrawy YA (2014) Glutamate excitotoxicity and neurodegeneration. J Mol Genet Med 8:4","journal-title":"J Mol Genet Med"},{"key":"741_CR76","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/ncb1441","volume":"8","author":"L Fallon","year":"2006","unstructured":"Fallon L, Belanger CM, Corera AT et al (2006) A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI 3\u00a0K-Akt signalling. Nat Cell Biol 8:834\u2013842","journal-title":"Nat Cell Biol"},{"key":"741_CR77","volume-title":"Brain lipids in synaptic function and neurological disease: clues to innovative therapeutic strategies for brain disorders","author":"J Fantini","year":"2015","unstructured":"Fantini J, Yahi N (2015) Brain lipids in synaptic function and neurological disease: clues to innovative therapeutic strategies for brain disorders. Academic Press, London"},{"issue":"9","key":"741_CR78","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/WNR.0b013e328354a1f0","volume":"23","author":"F Febbraro","year":"2012","unstructured":"Febbraro F, Giorgi M, Caldarola S, Loreni F, Romero-ramos M (2012) \u03b1-Synuclein expression is modulated at the translational level by iron. NeuroReport 23(9):576\u2013580","journal-title":"NeuroReport"},{"key":"741_CR79","doi-asserted-by":"crossref","first-page":"10047","DOI":"10.1021\/bi901090m","volume":"48","author":"D Fischer","year":"2009","unstructured":"Fischer D, Mukrasch MD, Biernat J, Bibow S, Blackledge M, Griesinger C et al (2009) Conformational changes specific for pseudophosphorylation at serine 262 selectively impair binding of tau to microtubules. Biochemistry 48:10047\u201310055","journal-title":"Biochemistry"},{"key":"741_CR80","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1749-6632.2003.tb07469.x","volume":"991","author":"G Fiskum","year":"2003","unstructured":"Fiskum G, Starkov A, Polster BM, Chinopoulos C (2003) Mitochondrial mechanisms of neural cell death and neuroprotective interventions in Parkinson\u2019s disease. Ann N Y Acad Sci 991:111\u2013119","journal-title":"Ann N Y Acad Sci"},{"key":"741_CR81","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1158\/1535-7163.MCT-12-0061","volume":"11","author":"DP Fitzgerald","year":"2012","unstructured":"Fitzgerald DP, Emerson DL, Qian Y et al (2012) TPI-287, a new taxane family member reduces the brain metastatic colonization of breast cancer cells. Mol Cancer Ther 11:1959\u20131967","journal-title":"Mol Cancer Ther"},{"key":"741_CR82","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.nrl.2015.03.012","volume":"33","author":"J Folch","year":"2018","unstructured":"Folch J, Ettcheto M, Petrov D, Abad S, Pedros I, Marin M et al (2018) Review of the advances in treatment for Alzheimer disease: strategies for combating \u03b2-amyloid protein. Neurologia 33:47\u201358","journal-title":"Neurologia"},{"issue":"2","key":"741_CR83","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1006\/bbrc.1997.6790","volume":"235","author":"TD Foley","year":"1997","unstructured":"Foley TD (1997) 5-HPETE is a potent inhibitor of neuronal Na K-ATPase activity. Biochem Biophys Res Commun 235(2):374\u2013376","journal-title":"Biochem Biophys Res Commun"},{"key":"741_CR84","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2147\/NDTS55104","volume":"10","author":"DJ Foster","year":"2014","unstructured":"Foster DJ, Choi DL, Conn PJ, Rook JM (2014) Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer\u2019s disease and schizophrenia. Neuropsychiatr Dis Treat 10:183. https:\/\/doi.org\/10.2147\/NDTS55104","journal-title":"Neuropsychiatr Dis Treat"},{"key":"741_CR85","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0116-6","author":"P Francesco","year":"2019","unstructured":"Francesco P, Madia L, Giancarlo L, Bruno PI (2019) A critical appraisal of amyloid-\u03b2-targeting therapies for Alzheimer disease. Nat Rev Neurol. https:\/\/doi.org\/10.1038\/s41582-018-0116-6","journal-title":"Nat Rev Neurol"},{"key":"741_CR86","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.neurobiolaging.2005.10.006","volume":"27","author":"M Freixes","year":"2006","unstructured":"Freixes M, Rodriguez A, Dalf\u00b4o E, Ferrer I (2006) Oxidation glycoxidation, lipoxidation, nitration, and responses to oxidative stress in the cerebral cortex in Creutzfeldt-Jakob disease. Neurobiol Aging 27:1807\u20131815","journal-title":"Neurobiol Aging"},{"key":"741_CR87","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00401-015-1484-2","volume":"130","author":"JP Fuller","year":"2015","unstructured":"Fuller JP, Stavenhagen JB, Christensen S, Kartberg F, Glennie MJ, Teeling JL (2015) Comparing the efficacy and neuroinflammatory potential of three anti- A\u03b2antibodies. Acta Neuropathol 130:699\u2013711","journal-title":"Acta Neuropathol"},{"key":"741_CR88","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1046\/j.1471-4159.1996.67051882.x","volume":"67","author":"K Furukawa","year":"1996","unstructured":"Furukawa K, Sopher BL, Rydel RE, Begley JG, Pham DG, Martin GM et al (1996) Increased activity-regulating and neuroprotective efficacy of \u03b1-secretase-derived secreted amyloid precursor protein conferred by a c-terminal heparin-binding domain. J Neurochem 67:1882\u20131896","journal-title":"J Neurochem"},{"key":"741_CR89","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1590\/S0004-282X2000000300030","volume":"58","author":"RJ Gagliardi","year":"2000","unstructured":"Gagliardi RJ (2000) Neuroprotection, excitotoxicity and NMDA antagonists. Arq Neuro-Psiquiatr 58:583\u2013588","journal-title":"Arq Neuro-Psiquiatr"},{"key":"741_CR90","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/ana.20819","volume":"59","author":"WR Galpern","year":"2006","unstructured":"Galpern WR, Lang AE (2006) Interface between tauopathies and synucleinopathies: a tale of two proteins. Ann Neurol 59:449\u2013458","journal-title":"Ann Neurol"},{"key":"741_CR91","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1086\/505914","volume":"194","author":"S Gauczynski","year":"2006","unstructured":"Gauczynski S, Nikles D, El-Gogo S et al (2006) The 37-kDa\/67-kDa laminin receptor acts as a receptor for infectious prions and is inhibited by polysulfated glycanes. J Infect Dis 194:702\u2013709","journal-title":"J Infect Dis"},{"issue":"10062","key":"741_CR92","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1016\/S0140-6736(16)31275-2","volume":"388","author":"S Gauthier","year":"2016","unstructured":"Gauthier S, Feldman HH, Schneider LS, Wilcock GK, Frisoni GB, Hardlund JH et al (2016) Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer\u2019s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. The Lancet 388(10062):2873\u20132884","journal-title":"The Lancet"},{"key":"741_CR93","doi-asserted-by":"crossref","first-page":"e4756","DOI":"10.1371\/journal.pone.0004756","volume":"4","author":"ME Gegg","year":"2009","unstructured":"Gegg ME, Cooper JM, Schapira AH, Taanman JW (2009) Silencing of PINK1 expression affects mitochondrial DNA and oxidative phosphorylation in dopaminergic cells. PLoS ONE 4:e4756","journal-title":"PLoS ONE"},{"key":"741_CR94","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nrneurol.2013.223","volume":"9","author":"E Giacobini","year":"2013","unstructured":"Giacobini E, Gold G (2013) Alzheimer disease therapy\u2014moving from amyloid-\u03b2 to tau. Nat Rev Neurol 9:677\u2013686","journal-title":"Nat Rev Neurol"},{"key":"741_CR95","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nm850","volume":"9","author":"SS Gill","year":"2003","unstructured":"Gill SS, Patel NK, Hotton GR et al (2003) Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 9:589\u2013595","journal-title":"Nat Med"},{"key":"741_CR96","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1242\/dmm.030205","volume":"10","author":"AD Gitler","year":"2017","unstructured":"Gitler AD, Dhillon P, Shorter J (2017) Neurodegenerative disease: models, mechanisms, and a new hope. Dis Models Mech 10:499\u2013502","journal-title":"Dis Models Mech"},{"issue":"10","key":"741_CR97","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/cmdc.200800124","volume":"3","author":"R Gitto","year":"2008","unstructured":"Gitto R, De-Luca L, Ferro S et al (2008) Computational studies to discover a new NR2B\/NMDA receptor antagonist and evaluation of pharmacological profile. Chem Med Chem 3(10):1539\u20131548","journal-title":"Chem Med Chem"},{"key":"741_CR98","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.bmc.2013.12.040","volume":"22","author":"R Gitto","year":"2014","unstructured":"Gitto R, De-Luca L, Ferro S et al (2014) Synthesis, modeling and biological characterization of 3-substituted-1H-indoles as ligands of GluN2B-containing Nmethyl- d-aspartate receptors. Bioorg Med Chem 22:1040\u20131048","journal-title":"Bioorg Med Chem"},{"key":"741_CR99","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1016\/j.bbamem.2013.06.005","volume":"1828","author":"TE Golde","year":"2013","unstructured":"Golde TE, Koo EH, Felsenstein KM, Osborne BA, Miele L (2013) \u03b3-Secretase inhibitors and modulators. Biochim Biophys Acta BBA-Biomembr 1828:2898\u20132907","journal-title":"Biochim Biophys Acta BBA-Biomembr"},{"key":"741_CR100","doi-asserted-by":"crossref","first-page":"5285","DOI":"10.1073\/pnas.0600813103","volume":"103","author":"MC Golding","year":"2006","unstructured":"Golding MC, Long CR, Carmell MA, Hannon GJ, Westhusin ME (2006) Suppression of prion protein in live-stock by RNA interference. Proc Natl Acad Sci 103:5285\u20135290","journal-title":"Proc Natl Acad Sci"},{"key":"741_CR101","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s12035-014-8689-6","volume":"51","author":"M Golpich","year":"2015","unstructured":"Golpich M, Rahmani B, Ibrahim NMAA et al (2015) Preconditioning as a potential strategy for the prevention of Parkinson\u2019s disease. Mol Neurobiol 51:313\u2013330","journal-title":"Mol Neurobiol"},{"key":"741_CR102","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.2174\/092986708785909111","volume":"15","author":"CX Gong","year":"2008","unstructured":"Gong CX, Iqbal K (2008) Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease. Curr Med Chem 15:2321\u20132328","journal-title":"Curr Med Chem"},{"key":"741_CR103","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0006-8993(96)00904-3","volume":"41","author":"CX Gong","year":"1996","unstructured":"Gong CX, Shaikh S, Grundke-Iqbal I, Iqbal K (1996) Inhibition of protein phosphatase-2B calcineurin activity towards Alzheimer abnormally phosphorylated \u03c4 by neuroleptics. Brain Res 41:95\u2013102","journal-title":"Brain Res"},{"issue":"7355","key":"741_CR104","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1038\/475S9a","volume":"475","author":"L Gravitz","year":"2011","unstructured":"Gravitz L (2011) Drugs: a tangled web of targets. Nature 475(7355):S9\u2013S11. https:\/\/doi.org\/10.1038\/475S9a","journal-title":"Nature"},{"key":"741_CR105","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1001\/jama.2009.1866","volume":"302","author":"RC Green","year":"2009","unstructured":"Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA et al (2009) Tarenflurbil Phase 3 Study Group: effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 302:2557\u20132564","journal-title":"JAMA"},{"issue":"5","key":"741_CR106","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1468-1331.2007.01727.x","volume":"14","author":"M Guttman","year":"2007","unstructured":"Guttman M, Boileau I, Warsh J, Saint-Cyr JA, Ginovart N, McCluskey T, Houle S, Wilson A, Mundo E, Rusjan P et al (2007) Brain serotonin transporter binding in nondepressed patients with Parkinson\u2019s disease. Eur J Neurol 14(5):523\u2013528","journal-title":"Eur J Neurol"},{"issue":"1","key":"741_CR107","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/1531-8257(200101)16:1<124::AID-MDS1007>3.0.CO;2-R","volume":"16","author":"TH Haapaniemi","year":"2001","unstructured":"Haapaniemi TH, Ahonen A, Torniainen P, Sotaniemi KA, Myllyla VV (2001) [123I]beta-CIT SPECT demonstrates decreased brain dopamine and serotonin transporter levels in untreated parkinsonian patients. Mov Disord 16(1):124\u2013130","journal-title":"Mov Disord"},{"key":"741_CR108","first-page":"37","volume":"16","author":"P Hallock","year":"2012","unstructured":"Hallock P, Michael A, Thomas (2012) Integrating the Alzheimer\u2019s disease proteome and transcriptome: a comprehensive network model of a complex disease. J Integr Biol 16:37\u201349","journal-title":"J Integr Biol"},{"key":"741_CR109","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1755-5949.2010.00147.x","volume":"16","author":"T Hamaguchi","year":"2010","unstructured":"Hamaguchi T, Ono K, Yamada M (2010) Review: curcumin and Alzheimer\u2019s disease. CNS Neurosci Ther 16:285\u2013297","journal-title":"CNS Neurosci Ther"},{"key":"741_CR110","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.molmed.2009.01.003","volume":"15","author":"DP Hanger","year":"2009","unstructured":"Hanger DP, Anderton BH, Noble W (2009) Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med 15:112\u2013119","journal-title":"Trends Mol Med"},{"key":"741_CR111","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0014-4886(95)90041-1","volume":"131","author":"ME Harris","year":"1995","unstructured":"Harris ME, Hensley K, Butterfield DA, Leedle RA, Carney JM (1995) Direct evidence of oxidative injury produced by the Alzheimer\u2019s \u03b2-amyloid peptide 1-40 in cultured hippocampal neurons. Exp Neurol 131:193\u2013202","journal-title":"Exp Neurol"},{"key":"741_CR112","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/nature10317","volume":"475","author":"FU Hart","year":"2011","unstructured":"Hart FU, Bracher A, Hayer-Hart M (2011) Molecular chaperones in protein folding and proteostasis. Nature 475:324\u2013332","journal-title":"Nature"},{"key":"741_CR113","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/sj.gt.3302349","volume":"11","author":"M Hashimoto","year":"2004","unstructured":"Hashimoto M, Rockenstei E, Mante M, Crews L, Bar-On P, Gage FH et al (2004) An anti-aggregation gene therapy strategy for lewy body disease utilizing \u03b2-synuclein lentivirus in a transgenic model. Gene Ther 11:1713\u20131723","journal-title":"Gene Ther"},{"issue":"6","key":"741_CR114","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s10863-009-9257-z","volume":"41","author":"TG Hastings","year":"2009","unstructured":"Hastings TG (2009) The role of dopamine oxidation in mitochondrial dysfunction: implications for Parkinson\u2019s disease. J Bioenerg Biomembr 41(6):469\u2013472","journal-title":"J Bioenerg Biomembr"},{"key":"741_CR115","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1212\/01.wnl.0000304044.22253.03","volume":"70","author":"K Haugarvoll","year":"2008","unstructured":"Haugarvoll K, Rademakers R, Kachergus JM et al (2008) LRRK2 R1441C Parkinsonism is clinically similar to sporadic Parkinson disease. Neurology 70:1456\u20131460","journal-title":"Neurology"},{"key":"741_CR116","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1523\/JNEUROSCI.3959-04.2005","volume":"25","author":"DY He","year":"2005","unstructured":"He DY, McGough NN, Ravindranathan A et al (2005) Glial cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption. J Neurosci 25:619\u2013628","journal-title":"J Neurosci"},{"key":"741_CR117","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S1474-4422(08)70117-0","volume":"7","author":"DG Healy","year":"2008","unstructured":"Healy DG, Falchi M, O\u2019Sullivan SS et al (2008) Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson\u2019s disease: a case-control study. Lancet Neurol 7:583\u2013590","journal-title":"Lancet Neurol"},{"issue":"8","key":"741_CR118","first-page":"1119","volume":"60","author":"LE Hebert","year":"2003","unstructured":"Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA (2003) Alzheimer disease in the US population: prevalence estimates using the 2000 census. JAMA Neurol 60(8):1119\u20131122","journal-title":"JAMA Neurol"},{"issue":"6","key":"741_CR119","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1073\/pnas.1308889111","volume":"111","author":"KL Hedstrom","year":"2014","unstructured":"Hedstrom KL, Murtie JC, Albers K, Calcutt NA, Corfas G (2014) Treating small fiber neuropathy by topical application of a small molecule modulator of ligand-induced GFR\u03b1\/RET receptor signalling. Proc Natl Acad Sci 111(6):2325\u20132330","journal-title":"Proc Natl Acad Sci"},{"issue":"7628","key":"741_CR120","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/539179a","volume":"539","author":"MT Heemels","year":"2016","unstructured":"Heemels MT (2016) Neurodegenerative diseases. Nature 539(7628):179","journal-title":"Nature"},{"key":"741_CR121","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev.biochem.67.1.425","volume":"67","author":"A Hershko","year":"1998","unstructured":"Hershko A, Ciechanover A (1998) The ubiquitin system. Ann Rev Biochem 67:425\u2013479","journal-title":"Ann Rev Biochem"},{"key":"741_CR122","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/cr.2013.70","volume":"23","author":"AZ Herskovits","year":"2013","unstructured":"Herskovits AZ, Guarente L (2013) Sirtuin deacetylases in neurodegenerative diseases of aging. Cell Res 23:746\u2013758","journal-title":"Cell Res"},{"key":"741_CR123","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1083\/jcb.201709172","volume":"216","author":"K Hibiki","year":"2017","unstructured":"Hibiki K, Giovanni M (2017) Proteinopathies and OXP HOS dysfunction in neurodegenerative diseases. J Cell Biol 216:3917\u20133929","journal-title":"J Cell Biol"},{"issue":"3","key":"741_CR124","first-page":"A110","volume":"120","author":"W Holtcamp","year":"2012","unstructured":"Holtcamp W (2012) The emerging science of BMAA: do cyanobacteria contribute to neurodegenerative disease? Environ Health Perspect 120(3):A110\u2013A116","journal-title":"Environ Health Perspect"},{"key":"741_CR125","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1021\/cn2000469","volume":"2","author":"CR Hopkins","year":"2011","unstructured":"Hopkins CR (2011) ACS chemical neuroscience molecule spotlight on ELND006: another \u03b3-secretase inhibitor fails in the clinic. ACS Chem Neurosci 2:279\u2013280","journal-title":"ACS Chem Neurosci"},{"key":"741_CR126","doi-asserted-by":"crossref","first-page":"F547","DOI":"10.1152\/ajprenal.00574.2014","volume":"310","author":"Y Hou","year":"2016","unstructured":"Hou Y, Li S, Wu M et al (2016) Mitochondria-targeted peptide SS-31 attenuates renal injury via an antioxidant effect in diabetic nephropathy. Am J Physiol Renal Physiol 310:F547\u2013F559","journal-title":"Am J Physiol Renal Physiol"},{"key":"741_CR127","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.expneurol.2017.10.026","volume":"300","author":"YL Hsieh","year":"2018","unstructured":"Hsieh YL, Kan HW, Chiang H, Lee YC, Hsieh ST (2018) Distinct TrkA and Ret modulated negative and positive neuropathic behaviors in a mouse model of resiniferatoxin-induced small fiber neuropathy. Exp Neurol 300:87\u201399","journal-title":"Exp Neurol"},{"issue":"1","key":"741_CR128","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.bbrc.2016.07.071","volume":"478","author":"H Hu","year":"2016","unstructured":"Hu H, Li M (2016) Mitochondria-targeted antioxidant mitotempo protects mitochondrial function against amyloid beta toxicity in primary cultured mouse neurons. Biochem Biophys Res Commun 478(1):174\u2013180","journal-title":"Biochem Biophys Res Commun"},{"key":"741_CR129","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1038\/nn1797","volume":"9","author":"X Hu","year":"2006","unstructured":"Hu X, Hicks CW, He W, Wong P, Macklin WB, Trapp BD et al (2006) Bace1 modulates myelination in the central and peripheral nervous system. Nat Neurosci 9:1520\u20131525","journal-title":"Nat Neurosci"},{"key":"741_CR130","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1586\/14737175.2015.1044981","volume":"15","author":"S Hu","year":"2015","unstructured":"Hu S, Maiti P, Ma Q, Zuo X, Jones MR, Cole GM, Frautschy SA (2015) Clinical development of curcumin in neurodegenerative disease. Expert Rev Neurother 15:629\u2013637","journal-title":"Expert Rev Neurother"},{"key":"741_CR131","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12929-017-0355-7","volume":"24","author":"SY Hung","year":"2017","unstructured":"Hung SY, Fu WM (2017) Drug candidates in clinical trials for Alzheimer\u2019s disease. J Biomed Sci 24:47","journal-title":"J Biomed Sci"},{"issue":"5","key":"741_CR132","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1021\/acschemneuro.6b00440","volume":"8","author":"P Huot","year":"2017","unstructured":"Huot P, Sgambato-Faure V, Fox SH, McCreary AC (2017) Serotonergic approaches in Parkinson\u2019s disease: translational perspectives, an update. ACS Chem Neurosci 8(5):973\u2013986","journal-title":"ACS Chem Neurosci"},{"issue":"214","key":"741_CR133","first-page":"e1","volume":"38","author":"J Infante","year":"2016","unstructured":"Infante J, Prieto C, Sierra M et al (2016) Comparative blood transcriptome analysis in idiopathic and LRRK2 G2019S-associated Parkinson\u2019s disease. Neurobiol Aging 38(214):e1\u2013e5","journal-title":"Neurobiol Aging"},{"key":"741_CR134","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.bbadis.2004.09.008","volume":"1739","author":"K Iqbal","year":"2005","unstructured":"Iqbal K, Alonso ADC, Chen S, Chohan MO, El-Akkad E, Gong CX et al (2005) Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta BBA Mol Basis Dis 1739:198\u2013210","journal-title":"Biochim Biophys Acta BBA Mol Basis Dis"},{"key":"741_CR135","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/jnen\/62.4.389","volume":"62","author":"T Ishizawa","year":"2003","unstructured":"Ishizawa T, Mattila P, Davies P, Wang D, Dickson DW (2003) Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. J Neuropathol Exp Neurol 62:389\u2013397","journal-title":"J Neuropathol Exp Neurol"},{"key":"741_CR136","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1602\/neurorx.2.4.612","volume":"2","author":"JS Jacobsen","year":"2005","unstructured":"Jacobsen JS, Reinhart P, Pangalos MN (2005) Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer\u2019s disease. NeuroRx 2:612\u2013626","journal-title":"NeuroRx"},{"key":"741_CR137","doi-asserted-by":"crossref","first-page":"11621","DOI":"10.1523\/JNEUROSCI.1405-14.2014","volume":"34","author":"H Jacobsen","year":"2014","unstructured":"Jacobsen H, Ozmen L, Caruso A, Narquizian R, Hilpert H, Jacobsen B, Terwel D, Tanghe A, Bohrmann B (2014) Combined treatment with a BACE inhibitor and anti- A\u03b2 antibody gantenerumab enhances amyloid reduction in APPLondon mice. J Neurosci 34:11621\u201311630","journal-title":"J Neurosci"},{"key":"741_CR138","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.bbadis.2011.02.013","volume":"1812","author":"S Jana","year":"2011","unstructured":"Jana S, Sinha M, Chanda D et al (2011) Mitochondrial dysfunction mediated by quinone oxidation products of dopamine: implications in dopamine cytotoxicity and pathogenesis of Parkinson\u2019s disease. Biochim Biophys Acta 1812:663\u2013673","journal-title":"Biochim Biophys Acta"},{"key":"741_CR139","doi-asserted-by":"crossref","first-page":"161S","DOI":"10.1212\/WNL.47.6_Suppl_3.161S","volume":"47","author":"P Jenner","year":"1996","unstructured":"Jenner P, Olanow CW (1996) Oxidative stress and the pathogenesis of Parkinson\u2019s disease. Neurology 47:161S\u2013170S","journal-title":"Neurology"},{"key":"741_CR140","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3233\/JAD-1999-14-512","volume":"1","author":"GVW Johnson","year":"1999","unstructured":"Johnson GVW, Hartigan JA (1999) Tau protein in normal and Alzheimer\u2019s disease brain: an update. J Alzheimer\u2019s Dis 1:329\u2013351","journal-title":"J Alzheimer\u2019s Dis"},{"issue":"16","key":"741_CR141","doi-asserted-by":"crossref","first-page":"6283","DOI":"10.1073\/pnas.1113248109","volume":"109","author":"BN Johnson","year":"2012","unstructured":"Johnson BN, Bergera AK, Cortesea GP, LaVoie MJ (2012) The ubiquitin E3 ligase parkin regulates the proapoptotic function of Bax. PNAS 109(16):6283\u20136288","journal-title":"PNAS"},{"key":"741_CR142","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1124\/jpet.112.192138","volume":"342","author":"A Johri","year":"2012","unstructured":"Johri A, Beal MF (2012) Mitochondrial dysfunction in neurodegenerative diseases. J Pharmacol Exp Ther 342:619\u2013630","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"741_CR144","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/sj.cdd.4401528","volume":"12","author":"H Kadowaki","year":"2005","unstructured":"Kadowaki H, Nishitoh H, Urano F et al (2005a) Amyloid \u03b2 induces neuronal cell death through ROS-mediated ASK1 activation. Cell Death Differ 12(1):19\u201324","journal-title":"Cell Death Differ"},{"key":"741_CR145","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/sj.cdd.4401528","volume":"12","author":"H Kadowaki","year":"2005","unstructured":"Kadowaki H, Nishitoh H, Urano F, Sadamitsu C, Matsuzawa A, Takeda K et al (2005b) Amyloid \u03b2 induces neuronal cell death through ROS-mediated ASK1 activation. Cell Death Differ 12:19\u201324","journal-title":"Cell Death Differ"},{"key":"741_CR146","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/sj.embor.7400188","volume":"5","author":"PJ Kahle","year":"2004","unstructured":"Kahle PJ, Haass C (2004) How does parkin ligate ubiquitin to Parkinson\u2019s disease? EMBO Rep 5:681\u2013685","journal-title":"EMBO Rep"},{"key":"741_CR147","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE (2015) Parkinson\u2019s disease. Lancet 386:896\u2013912","journal-title":"Lancet"},{"key":"741_CR148","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/nature10815","volume":"483","author":"Y Kanfi","year":"2012","unstructured":"Kanfi Y, Naiman S, Amir G et al (2012) The sirtuin SIRT6 regulates lifespan in male mice. Nature 483:218\u2013221","journal-title":"Nature"},{"key":"741_CR149","doi-asserted-by":"crossref","first-page":"12549","DOI":"10.1523\/JNEUROSCI.2080-16.2016","volume":"36","author":"KV Kastanenka","year":"2016","unstructured":"Kastanenka KV, Bussiere T, Shakerdge N, Qian F, Weinreb PH, Rhodes K, Bacskai BJ (2016) Immunotherapy with aducanumab restores calcium homeostasis in Tg2576 mice. J Neurosci 36:12549\u201312558","journal-title":"J Neurosci"},{"key":"741_CR150","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1046\/j.1471-4159.1999.0721224.x","volume":"72","author":"GI Keshet","year":"1999","unstructured":"Keshet GI, Ovadia H, Taraboulos A, Gabizon R (1999) Scrapie-infected mice and PrP knockout mice share abnormal localization and activity of neuronal nitric oxide synthase. J Neurochem 72:1224\u20131231","journal-title":"J Neurochem"},{"key":"741_CR151","doi-asserted-by":"crossref","first-page":"19440","DOI":"10.1074\/jbc.M112.346072","volume":"287","author":"N Kfoury","year":"2012","unstructured":"Kfoury N, Holmes BB, Jiang H, Holtzman DM, Diamond MI (2012) Trans-cellular propagation of Tau aggregation by fibrillar species. J Biol Chem 287:19440\u201319451","journal-title":"J Biol Chem"},{"key":"741_CR152","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.cbi.2009.06.024","volume":"181","author":"MT Khan","year":"2009","unstructured":"Khan MT, Orhan I, Senol FS et al (2009) Cholinesterase inhibitory activities of some flavonoid derivatives and chosen xanthone and their molecular docking studies. Chem Biol Interact 181:383\u2013389","journal-title":"Chem Biol Interact"},{"key":"741_CR153","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2008\/418765","volume":"8","author":"M Kiaei","year":"2008","unstructured":"Kiaei M (2008) Peroxisome proliferator-activated receptor gamma in amyotrophic lateral sclerosis and Huntington\u2019s disease. PPAR Res 8:1\u20138","journal-title":"PPAR Res"},{"key":"741_CR154","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/33416","volume":"392","author":"T Kitada","year":"1998","unstructured":"Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S (1998) Mutations in the parkin gene cause autosomal recessive juvenile Parkinsonism. Nature 392:605\u2013608","journal-title":"Nature"},{"key":"741_CR155","doi-asserted-by":"crossref","first-page":"25497","DOI":"10.1074\/jbc.M400255200","volume":"279","author":"J Klucken","year":"2004","unstructured":"Klucken J, Shin Y, Masliah E, Hyman BT, McLean PJ (2004) Hsp70 reduces \u03b1-synuclein aggregation and toxicity. J Biol Chem 279:25497\u201325502","journal-title":"J Biol Chem"},{"key":"741_CR156","doi-asserted-by":"publisher","first-page":"689285","DOI":"10.4061\/2009\/689285","volume":"2009","author":"H Kokubo","year":"2009","unstructured":"Kokubo H, Kayed R, Glabe CG, Staufenbiel M, Saido TC, Iwata N et al (2009) Amyloid beta annular protofibrils in cell processes and synapses accumulate with aging and Alzheimer-associated genetic modification. Int J Alzheimer\u2019s Dis 2009:689285. https:\/\/doi.org\/10.4061\/2009\/689285","journal-title":"Int J Alzheimer\u2019s Dis"},{"key":"741_CR157","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1073\/pnas.87.4.1561","volume":"874","author":"EH Koo","year":"1990","unstructured":"Koo EH, Sisodia SS, Archer DR, Martin LJ, Weidemann A, Beyreuther K et al (1990) Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport. Proc Natl Acad Sci 874:1561\u20131565","journal-title":"Proc Natl Acad Sci"},{"key":"741_CR158","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-019-01970-9","author":"SA Koren","year":"2019","unstructured":"Koren SA, Hamm MJ, Meier SE, Weiss BE, Nation GK, Chishti EA et al (2019) Tau drives translational selectivity by interacting with ribosomal proteins. Acta Neuropathol. https:\/\/doi.org\/10.1007\/s00401-019-01970-9","journal-title":"Acta Neuropathol"},{"issue":"12","key":"741_CR159","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s10822-009-9304-1","volume":"23","author":"BA Krueger","year":"2009","unstructured":"Krueger BA, Weil T, Schneider G (2009) Comparative virtual screening and novelty detection for NMDA-GlycineB antagonists. J Comput Aided Mol Des 23(12):869","journal-title":"J Comput Aided Mol Des"},{"issue":"1","key":"741_CR160","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jfma.2015.04.001","volume":"115","author":"A Kumar","year":"2016","unstructured":"Kumar A, Nisha CM, Silakari C et al (2016) Current and novel therapeutic molecules and targets in Alzheimer\u2019s disease. J Formos Med Assoc 115(1):3\u201310","journal-title":"J Formos Med Assoc"},{"key":"741_CR161","first-page":"659","volume":"62","author":"S Kuzuhara","year":"2010","unstructured":"Kuzuhara S (2010) Treatment strategy of Alzheimer disease: pause of clinical trials of A\u03b2 vaccine and next steps. Brain Nerve 62:659\u2013666","journal-title":"Brain Nerve"},{"key":"741_CR162","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/nm.2220","volume":"1611","author":"AE Lang","year":"2010","unstructured":"Lang AE (2010) Clinical trials of disease modifying therapies for neurodegenerative diseases: the challenges and the future. Nat Med 1611:1223\u20131226","journal-title":"Nat Med"},{"key":"741_CR163","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrn3406","volume":"14","author":"HA Lashuel","year":"2013","unstructured":"Lashuel HA, Overk CR, Oueslati A, Masliah E (2013) The many faces of alpha-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci 14:38\u201348","journal-title":"Nat Rev Neurosci"},{"key":"741_CR164","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nature14893","volume":"524","author":"M Lazarou","year":"2015","unstructured":"Lazarou M, Sliter DA, LA Kane JL et al (2015) The ubiquitin kinase PINK1 recruits autophagy receptors to induce mitophagy. Nature 524:309\u2013314","journal-title":"Nature"},{"issue":"10","key":"741_CR165","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1007\/s11064-009-9986-8","volume":"34","author":"SL Leong","year":"2009","unstructured":"Leong SL, Cappai R, Barnham KJ, Pham CL (2009) Modulation of alpha-synuclein aggregation by dopamine: a review. Neurochem Res 34(10):1838\u20131846","journal-title":"Neurochem Res"},{"key":"741_CR166","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1023\/B:TRAG.0000017177.35197.89","volume":"13","author":"C Leucht","year":"2004","unstructured":"Leucht C, Vana K, Renner-Muller I et al (2004) Knock-down of the 37-kDa laminin receptor in mouse brain by transgenic expression of specific antisense LRP RNA. Transgenic Res 13:81\u201385","journal-title":"Transgenic Res"},{"key":"741_CR167","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1152\/physrev.00007.2007","volume":"88","author":"R Linden","year":"2008","unstructured":"Linden R, Martins VR, Prado MA, Cammarota M, Izquierdo I, Brentani RR (2008) Physiology of the prion protein. Physiol Rev 88:673\u2013728","journal-title":"Physiol Rev"},{"key":"741_CR168","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2174\/1567205053585846","volume":"2","author":"SA Lipton","year":"2005","unstructured":"Lipton SA (2005) The molecular basis of memantine action in Alzheimer\u2019s disease and other neurologic disorders: low-affinity, uncompetitive antagonism. Curr Alzheimer Res 2:155\u2013165","journal-title":"Curr Alzheimer Res"},{"key":"741_CR169","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1750-1326-8-16","volume":"8","author":"O Liraz","year":"2013","unstructured":"Liraz O, Boehm-Cagan A, Michaelson D (2013) ApoE4 induces A\u03b242, tau and neuronal pathology in the hippocampus of young targeted replacement apoE4 mice. Mol Neurodegener 8:16","journal-title":"Mol Neurodegener"},{"key":"741_CR170","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1111\/j.1460-9568.2005.04391.x","volume":"22","author":"F Liu","year":"2005","unstructured":"Liu F, Grundke-Iqbal I, Iqbal K, Gong CX (2005) Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur J Neurosci 22:1942\u20131950","journal-title":"Eur J Neurosci"},{"issue":"2","key":"741_CR171","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","volume":"9","author":"C Liu","year":"2013","unstructured":"Liu C, Kanekiyo T, Xu H, Bu G (2013) Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 9(2):106\u2013118","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"741_CR172","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00401-015-1392-5","volume":"129","author":"AK Liu","year":"2015","unstructured":"Liu AK, Chang RC, Pearce RK, Gentleman SM (2015) Nucleus basalis of Meynert revisited: anatomy, history and differential involvement in Alzheimer\u2019s and Parkinson\u2019s disease. Acta Neuropathol 129(4):527\u2013540","journal-title":"Acta Neuropathol"},{"key":"741_CR173","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13195-016-0181-2","volume":"8","author":"V Logovinsky","year":"2016","unstructured":"Logovinsky V, Satlin A, Lai R, Swanson C, Kaplow J, Osswald G, Basun H, Lannfelt L (2016) Safety and tolerability of BAN2401\u2014 a clinical study in Alzheimer\u2019s disease with a protofibril selective A\u03b2 antibody. Alzheimers Res Ther 8:14","journal-title":"Alzheimers Res Ther"},{"key":"741_CR174","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S0959-4388(98)80122-0","volume":"8","author":"AM Lozano","year":"1998","unstructured":"Lozano AM, Lang AE, Hutchison WD, Dostrovsky JO (1998) New developments in understanding the etiology of Parkinson\u2019s disease and in its treatment. Curr Opin Neurobiol 8:783\u2013790","journal-title":"Curr Opin Neurobiol"},{"key":"741_CR175","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0002-9440(10)65184-X","volume":"155","author":"LF Lue","year":"1999","unstructured":"Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L (1999) Soluble amyloid \u03b2 peptide concentration as a predictor of synaptic change in Alzheimer\u2019s disease. Am J Pathol 155:853\u2013862","journal-title":"Am J Pathol"},{"key":"741_CR176","doi-asserted-by":"crossref","first-page":"12614","DOI":"10.1021\/bi801475r","volume":"47","author":"KC Luk","year":"2008","unstructured":"Luk KC, Mills IP, Trojanowski JQ, Lee VM (2008) Interactions between Hsp70 and the hydrophobic core of alpha-synuclein inhibit fibril assembly. Biochemistry 47:12614\u201312625","journal-title":"Biochemistry"},{"key":"741_CR177","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.12688\/f1000research.12681.1","volume":"6","author":"G Mackenzie","year":"2017","unstructured":"Mackenzie G, Will R (2017) Creutzfeldt-Jakob disease: recent developments. F1000 Res 6:2053","journal-title":"F1000 Res"},{"key":"741_CR178","doi-asserted-by":"publisher","DOI":"10.4155\/fso159","author":"R MacLeod","year":"2015","unstructured":"MacLeod R, Hillert EK, Cameron RT, Baillie GS (2015) The role and therapeutic targeting of \u03b1, \u03b2 and \u03b3 secretase in Alzheimer\u2019s disease. Future Sci. https:\/\/doi.org\/10.4155\/fso159","journal-title":"Future Sci"},{"issue":"Pt B","key":"741_CR179","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.bbr.2015.09.014","volume":"298","author":"P Maiti","year":"2016","unstructured":"Maiti P, Gregg LC, McDonald MP (2016) MPTP-induced executive dysfunction is associated with altered prefrontal serotonergic function. Behav Brain Res 298(Pt B):192\u2013201","journal-title":"Behav Brain Res"},{"key":"741_CR180","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3233\/JAD-2010-100564","volume":"20","author":"M Manczak","year":"2010","unstructured":"Manczak M, Mao P, Calkins MJ, Cornea A, Reddy AP, Murphy MP (2010) Mitochondria targeted antioxidants protect against amyloid-b toxicity in Alzheimer\u2019s disease neurons. J Alzheimer\u2019s Dis 20:609\u2013631","journal-title":"J Alzheimer\u2019s Dis"},{"key":"741_CR181","doi-asserted-by":"crossref","first-page":"373","DOI":"10.4161\/viru.24838","volume":"4","author":"L Manuelidis","year":"2013","unstructured":"Manuelidis L (2013) Infectious particles, stress, and induced prion amyloids: a unifying perspective. Virulence 4:373\u2013383","journal-title":"Virulence"},{"key":"741_CR182","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1471-4159.2008.05396.x","volume":"106","author":"M Marcade","year":"2008","unstructured":"Marcade M, Bourdin J, Loiseau N, Peillon H, Rayer A, Drouin D et al (2008) Etazolate, a neuroprotective drug linking GABAA receptor pharmacology to amyloid precursor protein processing. J Neurochem 106:392\u2013404","journal-title":"J Neurochem"},{"issue":"2","key":"741_CR183","first-page":"128","volume":"4","author":"SG Marina","year":"2013","unstructured":"Marina SG, Oleg SG (2013) The molecular chaperone GRP78\/BiP as a therapeutic target for neurodegenerative disorders: a mini review. J Genet Syndr Gene Ther 4(2):128","journal-title":"J Genet Syndr Gene Ther"},{"key":"741_CR184","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/mt.2012.28","volume":"20","author":"SG Marina","year":"2012","unstructured":"Marina SG, Arseniy S, Weijun C, Craig M, Layla FS, Max S, Jonathan HL, Alfred SL, Nicholas M, Oleg SG (2012) Glucose regulated protein 78 diminishes \u03b1-synuclein neurotoxicity in a rat model of Parkinson disease. Mol Ther 20:1327\u20131337","journal-title":"Mol Ther"},{"key":"741_CR185","doi-asserted-by":"crossref","first-page":"e19338","DOI":"10.1371\/journal.pone.0019338","volume":"6","author":"E Masliah","year":"2011","unstructured":"Masliah E, Rockenstein E, Mante M et al (2011) Passive immunization reduces behavioural and neuropathological deficits in an alpha-synuclein transgenic model of lewy body disease. PLoS ONE 6:e19338","journal-title":"PLoS ONE"},{"key":"741_CR186","first-page":"1150","volume":"3667","author":"V Mbazima","year":"2010","unstructured":"Mbazima V, Da-Costa-Dias B, Omar A, Jovanovic K, Weiss SF (2010) Interactions between PrP (c) and other ligands with the 37-kDa\/67-kDa laminin receptor. Front Biosci 3667:1150\u20131163","journal-title":"Front Biosci"},{"key":"741_CR187","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1083\/jcb.200810184","volume":"183","author":"HM McBride","year":"2008","unstructured":"McBride HM (2008) Parkin mitochondria in the autophagosome. J Cell Biol 183:757\u2013759","journal-title":"J Cell Biol"},{"key":"741_CR188","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1046\/j.1471-4159.2002.01190.x","volume":"83","author":"PJ McLean","year":"2002","unstructured":"McLean PJ, Kawamata H, Shariff S et al (2002a) Torsin-A and heat shock proteins act as molecular chaperones: suppression of \u03b1-synuclein aggregation. J Neurochem 83:846\u2013854","journal-title":"J Neurochem"},{"key":"741_CR189","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0268-0033(02)00017-7","volume":"17","author":"S McLean","year":"2002","unstructured":"McLean S, Naish R, Reed L, Urry S, Vicenzino B (2002b) A pilot study of the manual force levels required to produce manipulation induced hypoalgesia. Clin Biomech 17:304\u2013308","journal-title":"Clin Biomech"},{"key":"741_CR190","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/728983","author":"M Mehta","year":"2012","unstructured":"Mehta M, Adem A, Sabbagh M (2012) New acetylcholinesterase inhibitors for Alzheimer\u2019s disease. Int J Alzheimer\u2019s Dis. https:\/\/doi.org\/10.1155\/2012\/728983","journal-title":"Int J Alzheimer\u2019s Dis"},{"issue":"23\u201324","key":"741_CR191","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.drudis.2013.09.005","volume":"18","author":"BJ Melancon","year":"2013","unstructured":"Melancon BJ, Tarr JC, Panarese JD, Wood MR, Lindsley CW (2013) Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer\u2019s disease. Drug Dis Today 18(23\u201324):1185\u20131199","journal-title":"Drug Dis Today"},{"key":"741_CR192","first-page":"1","volume":"5","author":"SW Min","year":"2013","unstructured":"Min SW, Sohn PD, Cho SH, Swanson RA, Gan L (2013) Sirtuins in neurodegenerative diseases: an update on potential mechanisms. Front Aging Neurosci 5:1\u20139","journal-title":"Front Aging Neurosci"},{"key":"741_CR193","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/cns.12655","volume":"23","author":"G Mojtaba","year":"2017","unstructured":"Mojtaba G, Elham A, Zahurin M, Raymond AA, Norlinah MI, Abolhassan A (2017) Mitochondrial dysfunction and biogenesis in neurodegenerative diseases: pathogenesis treatment CNS. Neurosci Therapeut 23:5\u201322","journal-title":"Neurosci Therapeut"},{"key":"741_CR194","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/630182","author":"S Mondrag\u00f3n-Rodr\u00edguez","year":"2012","unstructured":"Mondrag\u00f3n-Rodr\u00edguez S, Perry G, Zhu X, Boehm J (2012) Amyloid beta and tau proteins as therapeutic targets for Alzheimer\u2019s disease treatment: rethinking the current strategy. Int J Alzheimer\u2019s Dis. https:\/\/doi.org\/10.1155\/2012\/630182","journal-title":"Int J Alzheimer\u2019s Dis"},{"key":"741_CR195","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3233\/JAD-2009-0972","volume":"16","author":"PI Moreira","year":"2009","unstructured":"Moreira PI, Duarte AI, Santos MS, Rego AC, Oliveira CR (2009) An integrative view of the role of oxidative stress, mitochondria and insulin in Alzheimer\u2019s disease. J Alzheimers Dis 16:741\u2013761","journal-title":"J Alzheimers Dis"},{"key":"741_CR196","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.bbadis.2009.10.007","volume":"1802","author":"PI Moreira","year":"2010","unstructured":"Moreira PI, Zhu X, Wang X, Lee HG, Nunomura A, Petersen RB, Perry G, Smith MA (2010) Mitochondria: a therapeutic target in neurodegeneration. Biochim Biophys Acta 1802:212\u2013220","journal-title":"Biochim Biophys Acta"},{"key":"741_CR197","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1101\/gad.1657108","volume":"22","author":"RI Morimoto","year":"2008","unstructured":"Morimoto RI (2008) Proteotoxic stress and inducible chaperone networks in neurodegenerative disease and aging. Genes Dev 22:427\u20131438","journal-title":"Genes Dev"},{"key":"741_CR199","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrn1587","volume":"6","author":"PJ Muchowski","year":"2005","unstructured":"Muchowski PJ, Wacker JL (2005a) Modulation of neurodegeneration by molecular chaperones. Nat Rev Neurosci 6:11\u201322","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"741_CR200","first-page":"11","volume":"6","author":"PJ Muchowski","year":"2005","unstructured":"Muchowski PJ, Wacker JL (2005b) Modulation of neurodegeneration by molecular chaperones. Neuroscience 6(1):11","journal-title":"Neuroscience"},{"key":"741_CR201","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0166-2236(00)02031-2","volume":"25","author":"A Mudher","year":"2002","unstructured":"Mudher A, Lovestone S (2002) Alzheimer\u2019s disease do tauists and baptists finally shake hands? Trends Neurosci 25:22\u201326","journal-title":"Trends Neurosci"},{"key":"741_CR202","volume-title":"Bradley\u2019s neurology in clinical practice","author":"ED Murray","year":"2012","unstructured":"Murray ED, Buttner EA, Price BH (2012) Depression and psychosis in neurological practice. In: Daroff R, Fenichel G, Jankovic J, Mazziotta J (eds) Bradley\u2019s neurology in clinical practice, 6th edn. Elsevier\/Saunders, Philadelphia","edition":"6"},{"key":"741_CR203","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1083\/jcb.200809125","volume":"183","author":"D Narendra","year":"2008","unstructured":"Narendra D, Tanaka A, Suen DF et al (2008) Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol 183:795\u2013803","journal-title":"J Cell Biol"},{"key":"741_CR204","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.redox.2014.01.017","volume":"2","author":"K Niforou","year":"2014","unstructured":"Niforou K, Cheimonidou C, Trougakos IP (2014) Molecular chaperones and proteostasis regulation during redox imbalance. Redox Biol 2:323\u2013332","journal-title":"Redox Biol"},{"key":"741_CR205","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/nature07767","volume":"457","author":"A Nikolaev","year":"2009","unstructured":"Nikolaev A (2009) APP binds DR6 to cause axon pruning and neuron death via distinct caspases. Nat 457:981\u2013989","journal-title":"Nat"},{"key":"741_CR206","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.bbadis.2009.07.014","volume":"1802","author":"IG Onyango","year":"2010","unstructured":"Onyango IG, Lu JH, Rodova M, Lezi E, Crafter AB, Swerdlow RH (2010) Regulation of neuron mitochondrial biogenesis and relevance to brain health. Biochim Biophys Acta 1802:228\u2013234","journal-title":"Biochim Biophys Acta"},{"key":"741_CR207","volume-title":"BioArctic announces positive topline results of BAN2401 Phase 2b at 18\u00a0months in early Alzheimer\u2019s disease","author":"G Osswald","year":"2018","unstructured":"Osswald G (2018) BioArctic announces positive topline results of BAN2401 Phase 2b at 18\u00a0months in early Alzheimer\u2019s disease. BioArctic Press Release, Stockholm"},{"key":"741_CR208","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1126\/science.1143780","volume":"317","author":"TF Outeiro","year":"2007","unstructured":"Outeiro TF, Kontopoulos E, Altmann SM et al (2007) Sirtuin 2 inhibitors rescue \u03b1-synuclein-mediated toxicity in models of Parkinson\u2019s disease. Science 317:516\u2013519","journal-title":"Science"},{"key":"741_CR209","doi-asserted-by":"crossref","first-page":"16856","DOI":"10.1074\/jbc.271.28.16856","volume":"271","author":"H Ovadia","year":"1996","unstructured":"Ovadia H, Rosenmann H, Shezen E, Halimi M, Ofran I, Gabizon R (1996) Effect of scrapie infection on the activity of neuronal nitricoxide synthase in brain and neuroblastoma cells. J Biol Chem 271:16856\u201316861","journal-title":"J Biol Chem"},{"key":"741_CR210","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.redox.2015.07.003","volume":"6","author":"M Pajares","year":"2015","unstructured":"Pajares M, Jim\u00e9nez-Moreno N, Dias IH et al (2015) Redox control of protein degradation. Redox Biol 6:409\u2013420","journal-title":"Redox Biol"},{"key":"741_CR211","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.neuroscience.2009.08.014","volume":"164","author":"T Pan","year":"2009","unstructured":"Pan T, Rawal P, Wu Y, Xie W, Jankovic J, Le W (2009) Rapamycin protects against rotenone-induced apoptosis through autophagy induction. Neuroscience 164:541\u2013551","journal-title":"Neuroscience"},{"key":"741_CR212","first-page":"176","volume":"2","author":"PK Panegyres","year":"2013","unstructured":"Panegyres PK, Armari E (2013) Therapies for human prion diseases. Am J Neurodegen Dis 2:176\u2013186","journal-title":"Am J Neurodegen Dis"},{"key":"741_CR213","doi-asserted-by":"crossref","first-page":"3245935","DOI":"10.1155\/2016\/3245935","volume":"2016","author":"F Panza","year":"2016","unstructured":"Panza F, Solfrizzi V, Seripa D, Imbimbo BP, Lozupone M, Santamato A, Zecca C, Barulli MR, Bellomo A, Pilotto A, Daniele A (2016) Tau-centric targets and drugs in clinical development for the treatment of Alzheimer\u2019s disease. Biomed Res Int 2016:3245935","journal-title":"Biomed Res Int"},{"key":"741_CR214","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s12640-013-9398-z","volume":"24","author":"CG Parson","year":"2013","unstructured":"Parson CG, Danysz W, Dekundy A, Pulte I (2013) Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer\u2019s disease. Neurotox Res 24:358\u2013369","journal-title":"Neurotox Res"},{"issue":"9433","key":"741_CR215","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(04)16811-6","volume":"364","author":"AH Peden","year":"2004","unstructured":"Peden AH, Head MW, Diane LR, Jeanne EB, James WI (2004) Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 364(9433):527\u2013529","journal-title":"Lancet"},{"issue":"5","key":"741_CR216","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/(SICI)1098-1004(200005)15:5<482::AID-HUMU16>3.0.CO;2-1","volume":"15","author":"K Peoc\u2019h","year":"2000","unstructured":"Peoc\u2019h K, Manivet P, Beaudry P et al (2000) Identification of three novel mutations E196\u00a0K, V203I, E211Q in the prion protein gene PRNP in inherited prion diseases with Creutzfeldt-Jakob disease phenotype. Human Mutat 15(5):482","journal-title":"Human Mutat"},{"key":"741_CR217","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s00401-005-1034-4","volume":"110","author":"RB Petersen","year":"2005","unstructured":"Petersen RB, Siedlak SL, Lee HG et al (2005) Redox metals and oxidative abnormalities in human prion diseases. Acta Neuropathol 110:232\u2013238","journal-title":"Acta Neuropathol"},{"key":"741_CR218","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/j.1471-4159.2006.04018.x","volume":"98","author":"S Petri","year":"2006","unstructured":"Petri S, Kiaei M, Damiano M et al (2006) Cell-permeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis. J Neurochem 98:1141\u20131148","journal-title":"J Neurochem"},{"key":"741_CR219","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1172\/JCI29236","volume":"116","author":"A Pfeifer","year":"2006","unstructured":"Pfeifer A, Eigenbrod S, Al-Khadra SM et al (2006) Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-Infected mice. J Clin Invest 116:3204\u20133210","journal-title":"J Clin Invest"},{"key":"741_CR220","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1099\/vir.0.004168-0","volume":"90","author":"H Pflanz","year":"2009","unstructured":"Pflanz H, Vana K, Mitteregger G et al (2009) Microinjection of lentiviral vectors expressing small interfering RNAs directed against laminin receptor precursor mRNA prolongs the pre-clinical phase in scrapie-infected mice. J Gen Virol 90:269\u2013274","journal-title":"J Gen Virol"},{"key":"741_CR221","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1074\/jbc.M410984200","volume":"280","author":"M Pickhardt","year":"2005","unstructured":"Pickhardt M, Gazova Z, Von-Bergen M, Khlistunova I, Wang Y, Hascher A, Mandelkow EM et al (2005) Anthraquinones inhibit tau aggregation and dissolve Alzheimer\u2019s paired helical filaments in vitro and in cells. J Biol Chem 280:3628\u20133635","journal-title":"J Biol Chem"},{"issue":"2","key":"741_CR222","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.neuron.2014.12.007","volume":"85","author":"AM Pickrell","year":"2015","unstructured":"Pickrell AM, Youle RJ (2015) The roles of PINK1 parkin, and mitochondrial fidelity in Parkinson\u2019s disease. Neuron 85(2):257\u2013273","journal-title":"Neuron"},{"key":"741_CR223","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/nm.3302","volume":"19","author":"M Pietri","year":"2013","unstructured":"Pietri M, Dakowski C, Hannaoui S, Alleaume-Butaux A, Hernandez-Rapp J, Ragagnin A et al (2013) PDK1 decreases TACE-mediated [alpha]-secretase activity and promotes disease progression in prion and Alzheimer\u2019s diseases. Nat Med 19:1124\u20131131","journal-title":"Nat Med"},{"key":"741_CR224","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s40263-014-0161-7","volume":"28","author":"A Pinna","year":"2014","unstructured":"Pinna A (2014) Adenosine A2A receptor antagonists in Parkinson\u2019s disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued. CNS Drugs 28:455\u2013474","journal-title":"CNS Drugs"},{"key":"741_CR225","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","volume":"276","author":"MH Polymeropoulos","year":"1997","unstructured":"Polymeropoulos MH, Lavedan C, Leroy E et al (1997) Mutation in the \u03b1-synuclein gene identified in families with Parkinson\u2019s disease. Science 276:2045\u20132047","journal-title":"Science"},{"key":"741_CR226","doi-asserted-by":"publisher","first-page":"829207","DOI":"10.1155\/2012\/829207","volume":"2012","author":"D Protter","year":"2012","unstructured":"Protter D, Lang C, Cooper AA (2012) \u03b1-Synuclein and mitochondrial dysfunction: a pathogenic partnership in Parkinson\u2019s disease. Parkinson\u2019s Dis 2012:829207. https:\/\/doi.org\/10.1155\/2012\/829207","journal-title":"Parkinson\u2019s Dis"},{"key":"741_CR227","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0092-8674(00)81163-0","volume":"93","author":"SB Prusiner","year":"1998","unstructured":"Prusiner SB, Scott MR, DeArmond SJ, Cohen FE (1998) Prion protein biology. Cell 93:337\u2013348","journal-title":"Cell"},{"issue":"4","key":"741_CR228","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1046\/j.1471-4159.2002.01210.x","volume":"83","author":"L Qin","year":"2002","unstructured":"Qin L, Liu Y, Cooper C, Liu B, Wilson B, Hong JS (2002) Microglia enhance \u03b2-amyloid peptide-induced toxicity in cortical and mesencephalic neurons by producing reactive oxygen species. J Neurochem 83(4):973\u2013983","journal-title":"J Neurochem"},{"issue":"11","key":"741_CR229","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/j.neurobiolaging.2005.09.036","volume":"27","author":"B Qin","year":"2006","unstructured":"Qin B, Cartier L, Dubois-dauphin M, Li B, Serrander L, Krause KH (2006) A key role for the microglial NADPH oxidase in APP-dependent killing of neurons. Neurobiol Aging 27(11):1577\u20131587","journal-title":"Neurobiol Aging"},{"key":"741_CR230","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.molbrainres.2005.04.012","volume":"138","author":"CA Rankin","year":"2005","unstructured":"Rankin CA, Sun Q, Gamblin TC (2005) Pseudo-phosphorylation of tau at Ser202 and Thr205 affects tau filament formation. Mol Brain Res 138:84\u201393","journal-title":"Mol Brain Res"},{"key":"741_CR231","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0140-6736(05)71083-7","volume":"365","author":"O Rascol","year":"2005","unstructured":"Rascol O, Brooks DJ, Melamed E et al (2005) LARGO Study Group Rasagiline as an adjunct to levodopa in patients with Parkinson\u2019s disease and motor fluctuations LARGO, Lasting effect in Adjunct therapy with Rasagiline given once daily, study: a randomised, double-blind, parallel-group trial. Lancet 365:947\u2013954","journal-title":"Lancet"},{"key":"741_CR232","doi-asserted-by":"crossref","first-page":"e1005401","DOI":"10.1371\/journal.ppat.1005401","volume":"28","author":"RR Reimann","year":"2016","unstructured":"Reimann RR, Sonati T, Hornemann S et al (2016) Differential toxicity of antibodies to the prion protein. PLoS Pathog 28:e1005401","journal-title":"PLoS Pathog"},{"key":"741_CR233","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1474-4422(10)70043-0","volume":"9","author":"JO Rinne","year":"2010","unstructured":"Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE et al (2010) 11 C-PiB PET assessment of change in fibrillar amyloid-\u03b2 load in patients with Alzheimer\u2019s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 9:363\u2013372","journal-title":"Lancet Neurol"},{"key":"741_CR234","unstructured":"Rogers MB (2018) To block tau\u2019s proteopathic spread, antibody must attack its mid-region. Alzforum. https:\/\/www.alzforum.org\/news\/conference-coverage\/blocktaus-proteopathic-spread-antibody-ustattack-its-mid-region"},{"key":"741_CR235","doi-asserted-by":"crossref","first-page":"6313","DOI":"10.1016\/j.bmc.2012.09.005","volume":"20","author":"KK Roy","year":"2012","unstructured":"Roy KK, Tota S, Tripathi T, Chander S, Nath C, Saxena AK (2012) Lead optimization studies towards the discovery of novel carbamates as potent AChE inhibitors for the potential treatment of Alzheimer\u2019s disease. Bioorg Med Chem 20:6313\u20136320","journal-title":"Bioorg Med Chem"},{"issue":"2","key":"741_CR236","first-page":"3","volume":"10","author":"R Rubenstein","year":"2017","unstructured":"Rubenstein R (2017) Possible causes of Alzheimer\u2019s disease related Amyloid-\u03b2 plaques and neurofibrillary tangles. Sci J Lander Coll Arts Sci 10(2):3","journal-title":"Sci J Lander Coll Arts Sci"},{"key":"741_CR237","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.amjopharm.2009.06.003","volume":"7","author":"MN Sabbagh","year":"2009","unstructured":"Sabbagh MN (2009) Drug development for Alzheimer\u2019s disease: where are we now and where are we headed? Am J Geriatric Pharmacother 7:167\u2013185","journal-title":"Am J Geriatric Pharmacother"},{"key":"741_CR238","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","volume":"370","author":"S Salloway","year":"2014","unstructured":"Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M et al (2014) Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease. New Engl J Med 370:322\u2013333","journal-title":"New Engl J Med"},{"key":"741_CR239","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(04)16305-8","volume":"363","author":"A Samii","year":"2004","unstructured":"Samii A, Nutt JG, Ransom BR (2004) Parkinson\u2019s Dis. Lancet 363:1183\u20131193","journal-title":"Lancet"},{"key":"741_CR240","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.pnpbp.2013.05.008","volume":"45","author":"MG Sanchez","year":"2013","unstructured":"Sanchez MG, Morissette M, Di Paolo T (2013) Estradiol and brain serotonin reuptake transporter in long-term ovariectomized parkinsonian monkeys. Prog Neuro-Psychopharmacol Biol Psychiatry 45:170\u2013177","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"741_CR241","unstructured":"Sattar H (2013) Fundamentals of pathology. Pathoma LLC; 2nd edition 2013"},{"key":"741_CR242","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1152\/physrev.00025.2007","volume":"88","author":"RC Scarpulla","year":"2008","unstructured":"Scarpulla RC (2008) Transcriptional paradigms in mammalian mitochondrial biogenesis and function. Physiol Rev 88:611\u2013638","journal-title":"Physiol Rev"},{"key":"741_CR243","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.bbamcr.2010.09.019","volume":"1813","author":"RC Scarpulla","year":"2011","unstructured":"Scarpulla RC (2011) Metabolic control of mitochondrial Biogenesis through the PGC-1 family regulatory network. Biochim Biophys Acta 1813:1269\u20131278","journal-title":"Biochim Biophys Acta"},{"key":"741_CR245","first-page":"271","volume":"534","author":"NK Scott","year":"2013","unstructured":"Scott NK (2013) Infection prevention: review and update for neurodiagnostic technologists. Neurodiag J 534:271\u2013288","journal-title":"Neurodiag J"},{"key":"741_CR246","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2202-15-9","volume":"15","author":"J Sharma","year":"2014","unstructured":"Sharma J, Johnston MV, Hossain MA (2014) Sex differences in mitochondrial biogenesis determine neuronal death and survival in response to oxygen glucose deprivation and reoxygenation. BMC Neurosci 15:1\u201314","journal-title":"BMC Neurosci"},{"issue":"1","key":"741_CR247","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1471-4159.2008.05347.x","volume":"106","author":"PB Shelat","year":"2008","unstructured":"Shelat PB, Chalimoniuk M, Wang JH et al (2008) Amyloid beta peptide and NMDA induce ROS from NADPH oxidase and AA release from cytosolic phospholipase A2 in cortical neurons. J Neurochem 106(1):45\u201355","journal-title":"J Neurochem"},{"key":"741_CR248","doi-asserted-by":"crossref","first-page":"6692","DOI":"10.1016\/j.bmc.2009.07.072","volume":"17","author":"R Sheng","year":"2009","unstructured":"Sheng R, Lin X, Zhang J, Chol KS, Huang W, Yang B et al (2009) Design, synthesis and evaluation of flavonoid derivatives as potent AChE inhibitors. Bioorg Med Chem 17:6692\u20136698","journal-title":"Bioorg Med Chem"},{"key":"741_CR249","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/77060","volume":"25","author":"H Shimura","year":"2000","unstructured":"Shimura H, Hattori N, Kubo SI et al (2000) Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 25:302\u2013305","journal-title":"Nat Genet"},{"key":"741_CR250","first-page":"10","volume":"17","author":"K Shin-ichiro","year":"2013","unstructured":"Shin-ichiro K, Taku H, Masashi T, Nobutaka H (2013) Can parkin be a target for future treatment of Parkinson\u2019s disease? Expert Opin Ther Targets 17:10","journal-title":"Expert Opin Ther Targets"},{"issue":"4","key":"741_CR251","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1134\/S0026893316040105","volume":"50","author":"YA Sidorova","year":"2016","unstructured":"Sidorova YA, Saarma M (2016) Glial cell line-derived neurotrophic factor family ligands and their therapeutic potential. Mol Biol 50(4):521\u2013531","journal-title":"Mol Biol"},{"key":"741_CR252","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3389\/fphar.2017.00365","volume":"8","author":"YA Sidorova","year":"2017","unstructured":"Sidorova YA, Bespalov MM, Wong AWTO et al (2017) A novel small molecule GDNF receptor RET agonist, BT13, promotes neurite growth from sensory neurons in vitro and attenuates experimental neuropathy in the rat. Front Pharmacol 8:365","journal-title":"Front Pharmacol"},{"issue":"3","key":"741_CR253","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3233\/JAD-151101","volume":"51","author":"S Simonovitch","year":"2016","unstructured":"Simonovitch S, Schmukler E, Pinkas-Kramarski R et al (2016) Impaired autophagy in APOE4 astrocytes. J Alzheimer\u2019s Dis JAD 51(3):915\u2013927","journal-title":"J Alzheimer\u2019s Dis JAD"},{"key":"741_CR254","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3171\/jns.2005.102.2.0216","volume":"102","author":"JT Slevin","year":"2005","unstructured":"Slevin JT, Gerhardt GA, Smith CD, Gash DM, Kryscio R, Young B (2005) Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J Neurosurg 102:216\u2013222","journal-title":"J Neurosurg"},{"issue":"8","key":"741_CR255","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1016\/j.bbamem.2007.02.002","volume":"1768","author":"DG Smith","year":"2007","unstructured":"Smith DG, Cappa R, Barnham KJ (2007) The redox chemistry of the Alzheimer\u2019s disease amyloid \u03b2 peptide. Biochim Biophys Acta 1768(8):1976\u20131990","journal-title":"Biochim Biophys Acta"},{"key":"741_CR256","doi-asserted-by":"crossref","first-page":"292","DOI":"10.5607\/en.2014.23.4.292","volume":"23","author":"D Snead","year":"2014","unstructured":"Snead D, Eliezer D (2014) Alpha-synuclein function and dysfunction on cellular membranes. Exp Neurobiol 23:292\u2013313","journal-title":"Exp Neurobiol"},{"key":"741_CR257","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/BF01244786","volume":"74","author":"E Sofic","year":"1988","unstructured":"Sofic E, Riederer P, Heinsen H et al (1988) Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm 74:199\u2013205","journal-title":"J Neural Transm"},{"key":"741_CR258","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1111\/j.1600-0854.2010.01090.x","volume":"11","author":"EB Sorensen","year":"2010","unstructured":"Sorensen EB, Conner SD (2010) \u03b3-secretase dependent cleavage initiates notch signalling from the plasma membrane. Trafficking 11:1234\u20131245","journal-title":"Trafficking"},{"key":"741_CR259","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/jnc.13691","volume":"139","author":"S Sveinbjornsdottir","year":"2016","unstructured":"Sveinbjornsdottir S (2016) The clinical symptoms of Parkinson\u2019s disease. J Neurochem 139:318\u2013324","journal-title":"J Neurochem"},{"key":"741_CR260","first-page":"535","volume-title":"Cell-permeable, mitochondrial-targeted, peptide antioxidants.Drug addiction","author":"HH Szeto","year":"2008","unstructured":"Szeto HH (2008) Cell-permeable, mitochondrial-targeted, peptide antioxidants.Drug addiction. Springer, New York, pp 535\u2013546"},{"issue":"1\u20133","key":"741_CR261","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0022-510X(83)90203-4","volume":"62","author":"F Tagliavini","year":"1983","unstructured":"Tagliavini F, Pilleri G (1983) Basal nucleus of Meynert, a neuropathological study in Alzheimer\u2019s disease, simple senile dementia, Pick\u2019s disease and Huntington\u2019s chorea. J Neurol Sci 62(1\u20133):243\u2013260","journal-title":"J Neurol Sci"},{"key":"741_CR262","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1099\/vir.0.2008\/001255-0","volume":"89","author":"G Tamg\u00fcney","year":"2008","unstructured":"Tamg\u00fcney G, Giles K, Glidden DV, Lessard P, Wille H, Tremblay P (2008) Genes contributing to prion pathogenesis. J Gen Virol 89:1777\u20131788","journal-title":"J Gen Virol"},{"key":"741_CR263","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2174\/1874082000903010026","volume":"3","author":"Z Tan","year":"2009","unstructured":"Tan Z, Shi L, Schreiber SS (2009a) Differential expression of redox factor-1 associated with beta-amyloid-mediated neurotoxicity. Open Neurosci J 3:26\u201334","journal-title":"Open Neurosci J"},{"key":"741_CR264","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2174\/1874082000903010026","volume":"J3","author":"Z Tan","year":"2009","unstructured":"Tan Z, Shi L, Schreiber SS (2009b) Differential expression of redox factor-1 associated with beta-amyloid-mediated neurotoxicity. Open Neurosci J3:26\u201334","journal-title":"Open Neurosci"},{"issue":"3","key":"741_CR265","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.neuropharm.2011.01.006","volume":"61","author":"SK Tan","year":"2011","unstructured":"Tan SK, Hartung H, Sharp T, Temel Y (2011) Serotonin-dependent depression in Parkinson\u2019s disease: a role for the subthalamic nucleus? Neuropharmacol 61(3):387\u2013399","journal-title":"Neuropharmacol"},{"key":"741_CR266","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.trci.2018.02.002","volume":"4","author":"PN Tariot","year":"2018","unstructured":"Tariot PN, Lopera F, Langbaum JB et al (2018) The alzheimer\u2019s prevention initiative autosomal- dominant alzheimer\u2019s disease trial: a study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal- dominant Alzheimer\u2019s disease, including a placebo- treated noncarrier cohort. Alzheimers Dement 4:150\u2013160","journal-title":"Alzheimers Dement"},{"key":"741_CR267","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2174\/1570159X13666151030102847","volume":"14","author":"JM Taymansa","year":"2016","unstructured":"Taymansa JM, Greggio E (2016) LRRK2 Kinase Inhibition as a therapeutic strategy for Parkinson\u2019s disease, where do we stand. Curr Neuropharmacol 14:214\u2013225","journal-title":"Curr Neuropharmacol"},{"key":"741_CR268","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/S0006-291X(03)00805-2","volume":"305","author":"G Tilly","year":"2003","unstructured":"Tilly G, Chapuis J, Vilette D, Laude H, Vilotte JL (2003) Efficient and specific downregulation of prion protein expression by RNAi. Biochem Biophys Res Commun 305:548\u2013551","journal-title":"Biochem Biophys Res Commun"},{"key":"741_CR269","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1212\/01.WNL.0000129697.01779.0A","volume":"62","author":"P Tiraboschi","year":"2004","unstructured":"Tiraboschi P, Hansen LA, Thal LJ, Corey-Bloom J (2004) The importance of neuritic plaques and tangles to the development and evolution of AD. Neurol 62:1984\u20131989","journal-title":"Neurol"},{"issue":"1","key":"741_CR270","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0197-0186(02)00053-0","volume":"42","author":"K Tokugawa","year":"2003","unstructured":"Tokugawa K, Yamamoto K, Nishiguchi M et al (2003) XIB4035, a novel nonpeptidyl small molecule agonist for GFR\u03b1-1. Neurochem Int 42(1):81\u201386","journal-title":"Neurochem Int"},{"key":"741_CR271","doi-asserted-by":"crossref","first-page":"39374","DOI":"10.1038\/srep39374","volume":"6","author":"M Ultsch","year":"2016","unstructured":"Ultsch M, Li B, Maurer T, Mathieu M, Adolfsson O, Muhs A, Pfeifer A, Pihlgren M, Bainbridge TW, Reichelt M, Ernst JA (2016) Structure of crenezumab complex with A\u03b2 shows loss of \u03b2- hairpin. Sci Rep 6:39374","journal-title":"Sci Rep"},{"issue":"4","key":"741_CR272","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/vox.12371","volume":"110","author":"PJ Urwin","year":"2016","unstructured":"Urwin PJ, Mackenzie JM, Llewelyn CA, Will RG, Hewitt PE (2016) Creutzfeldt-Jakob disease and blood transfusion: updated results of the UK transfusion medicine epidemiology review study. Vox Sang 110(4):310\u2013316","journal-title":"Vox Sang"},{"key":"741_CR277","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1126\/science.1096284","volume":"304","author":"EM Valente","year":"2004","unstructured":"Valente EM, Abou-Sleiman PM, Caputo V et al (2004) Hereditary early-onset Parkinson\u2019s disease caused by mutations in PINK1. Science 304:1158\u20131160","journal-title":"Science"},{"key":"741_CR278","doi-asserted-by":"crossref","first-page":"13888","DOI":"10.1073\/pnas.1009038107","volume":"107","author":"J Van-Eersel","year":"2010","unstructured":"Van-Eersel J, Ke YD, Liu X, Delerue F, Kril JJ, Gotz J, Ittner LM (2010) Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer\u2019s disease models. Proc Natl Acad Sci 107:13888\u201313893","journal-title":"Proc Natl Acad Sci"},{"key":"741_CR279","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/653962","author":"KR Varadaraju","year":"2013","unstructured":"Varadaraju KR, Kumar JR, Mallesha L et al (2013) Virtual screening and biological evaluation of piperazine derivatives as human acetylcholinesterase inhibitors. Int J Alzheimers Dis. https:\/\/doi.org\/10.1155\/2013\/653962","journal-title":"Int J Alzheimers Dis"},{"key":"741_CR280","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1096\/fj.11-200295","volume":"267","author":"LJ Vella","year":"2012","unstructured":"Vella LJ, Cappai R (2012) Identification of a novel amyloid precursor protein processing pathway that generates secreted N-terminal fragments. FASEB J 267:2930\u20132940","journal-title":"FASEB J"},{"key":"741_CR281","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2174\/156720511795256053","volume":"8","author":"B Vellas","year":"2011","unstructured":"Vellas B, Sol O, Snyder PJ, Ousset PJ, Haddad R, Maurin M et al (2011) EHT0202 in Alzheimer\u2019s disease: a 3-month, randomized, placebo-controlled, double-blind study. Curr Alzheimer Res 8:203\u2013212","journal-title":"Curr Alzheimer Res"},{"issue":"28","key":"741_CR282","doi-asserted-by":"crossref","first-page":"9090","DOI":"10.1523\/JNEUROSCI.1357-09.2009","volume":"29","author":"X Wang","year":"2009","unstructured":"Wang X, Su BO, Lee HG, Li X, Perry G, Smith MA, Zhu X (2009) Impaired balance of mitochondrial fission and fusion in Alzheimer\u2019s disease. J Neurosci 29(28):9090\u20139103","journal-title":"J Neurosci"},{"key":"741_CR283","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1523\/JNEUROSCI.5077-10.2011","volume":"31","author":"A Wang","year":"2011","unstructured":"Wang A, Das P, Switzer RC, Golde TE, Jankowsky JL (2011) Robust amyloid clearance in a mouse model of Alzheimer\u2019s disease provides novel insights into the mechanism of amyloid-\u03b2 immunotherapy. J Neurosci 31:4124\u20134136","journal-title":"J Neurosci"},{"issue":"1","key":"741_CR284","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/ana.20708","volume":"59","author":"HJ Ward","year":"2006","unstructured":"Ward HJ, Everington D, Cousens SN, Smith-Bathgate B, Leitch M, Cooper S, Heath C, Knight RS, Smith PG, Will RG (2006) Risk factors for variant Creutzfeldt-Jakob disease: a case-control study. Ann Neurol 59(1):111\u2013120","journal-title":"Ann Neurol"},{"key":"741_CR285","first-page":"285","volume":"3","author":"T West","year":"2016","unstructured":"West T (2016) Safety, tolerability and pharmacokinetics of ABBV-8E12, a humanized anti-tau monoclonal antibody, in a Phase I, single ascending dose, placebo controlled study in subjects with progressive supranuclear palsy. J Prev Alzheimers Dis 3:285","journal-title":"J Prev Alzheimers Dis"},{"key":"741_CR286","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4161\/pri.3.3.9289","volume":"3","author":"MD White","year":"2009","unstructured":"White MD, Mallucci GR (2009) Therapy for prion diseases Insights from the use of RNA interference. Prion 3:121\u2013128","journal-title":"Prion"},{"key":"741_CR288","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/bmb\/66.1.255","volume":"66","author":"RG Will","year":"2003","unstructured":"Will RG (2003) Acquired prion disease: iatrogenic CJD, variant CJD, kuru. Br Med Bull 66:255\u2013265","journal-title":"Br Med Bull"},{"issue":"5","key":"741_CR289","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/1531-8249(200005)47:5<575::AID-ANA4>3.0.CO;2-W","volume":"47","author":"RG Will","year":"2000","unstructured":"Will RG, Zeidler M, Stewart GE, Macleod MA, Ironside JW, Cousens SN, Mackenzie J, Estibeiro K, Green AJ, Knight RS (2000) Diagnosis of new variant Creutzfeldt\u2013Jakob disease. Ann Neurol 47(5):575\u2013582","journal-title":"Ann Neurol"},{"key":"741_CR290","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1474-4422(12)70140-0","volume":"11","author":"B Winblad","year":"2012","unstructured":"Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, Dumortier T, Maguire RP, Blennow K, Lundmark J, Staufenbiel M, Orgogozo JM (2012) Safety, tolerability, and antibody response of active A\u03b2 immunotherapy with CAD106 in patients with Alzheimer\u2019s disease: randomised, double- blind, placebo- controlled first- in-human study. Lancet Neurol 11:597\u2013604","journal-title":"Lancet Neurol"},{"key":"741_CR291","doi-asserted-by":"crossref","first-page":"11213","DOI":"10.1073\/pnas.93.20.11213","volume":"93","author":"CM Wischik","year":"1996","unstructured":"Wischik CM, Edwards PC, Lai RY, Roth M, Harrington CR (1996) Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci USA 93:11213\u201311218","journal-title":"Proc Natl Acad Sci USA"},{"issue":"120","key":"741_CR292","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1471-4159.2011.07501.x","volume":"1","author":"MS Wolfe","year":"2012","unstructured":"Wolfe MS (2012) \u03b3-Secretase inhibitors and modulators for Alzheimer\u2019s disease. J Neurochem 1(120):89\u201398","journal-title":"J Neurochem"},{"key":"741_CR293","doi-asserted-by":"crossref","first-page":"23009","DOI":"10.1074\/jbc.M414648200","volume":"280","author":"HK Wong","year":"2005","unstructured":"Wong HK, Sakurai T, Oyama F, Kaneko K, Wada K, Miyazaki H et al (2005) Beta Subunits of voltage-gated sodium channels are novel substrates of beta-site amyloid precursor protein-cleaving enzyme BACE1 and gamma-secretase. J Biol Chem 280:23009\u201323017","journal-title":"J Biol Chem"},{"key":"741_CR294","doi-asserted-by":"crossref","first-page":"14379","DOI":"10.1073\/pnas.0606714103","volume":"103","author":"Z Wu","year":"2006","unstructured":"Wu Z, Huang X, Feng Y et al (2006) Transducer of regulated CREB-binding proteins (TORCs) induce PGC-1 alpha transcription and mitochondrial biogenesis in muscle cells. Proc Natl Acad Sci 103:14379\u201314384","journal-title":"Proc Natl Acad Sci"},{"key":"741_CR295","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13024-015-0004-0","volume":"10","author":"W Xiang","year":"2015","unstructured":"Xiang W, Menges S, Schlachetzki JC et al (2015) Posttranslational modification and mutation of histidine 50 trigger alpha synuclein aggregation and toxicity. Mol Neurodegener 10:8","journal-title":"Mol Neurodegener"},{"key":"741_CR296","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.neuron.2013.07.046","volume":"80","author":"K Yanamandra","year":"2013","unstructured":"Yanamandra K, Kfoury N, Jiang H et al (2013) Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 80:402\u2013414","journal-title":"Neuron"},{"key":"741_CR297","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/acn3.176","volume":"2","author":"K Yanamandra","year":"2015","unstructured":"Yanamandra K, Jiang H, Mahan TE, Maloney SE, Wozniak DF, Diamond MI, Holtzman DM (2015) Anti-tau antibody reduces insoluble tau and decreases brain atrophy. Ann Clin Transl Neurol 2:278\u2013288","journal-title":"Ann Clin Transl Neurol"},{"key":"741_CR298","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1089\/ars.2009.2445","volume":"11","author":"L Yang","year":"2009","unstructured":"Yang L, Zhao K, Calingasan NY, Luo G, Szeto HH, Beal MF (2009) Mitochondria targeted peptides protect against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine neurotoxicity. Antioxid Redox Signal 11:2095\u20132104","journal-title":"Antioxid Redox Signal"},{"key":"741_CR299","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1161\/STROKEAHA.108.520114","volume":"39","author":"W Yin","year":"2008","unstructured":"Yin W, Signore AP, Iwai M, Cao GD, Gao YQ, Chen J (2008) Rapidly increased neuronal mitochondrial biogenesis after hypoxic-ischemic brain injury. Stroke 39:3057\u20133063","journal-title":"Stroke"},{"issue":"1","key":"741_CR300","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrm3028","volume":"12","author":"RJ Youle","year":"2011","unstructured":"Youle RJ, Narendra DP (2011) Mechanisms of mitophagy. Nat Rev Mol Cell Biol 12(1):9\u201314","journal-title":"Nat Rev Mol Cell Biol"},{"key":"741_CR301","doi-asserted-by":"crossref","first-page":"10892","DOI":"10.1074\/jbc.M800102200","volume":"283","author":"H Zhang","year":"2008","unstructured":"Zhang H, Bosch-Marce M, Shimoda LA et al (2008) Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J Biol Chem 283:10892\u201310903","journal-title":"J Biol Chem"},{"key":"741_CR302","doi-asserted-by":"crossref","first-page":"18325","DOI":"10.1074\/jbc.M117.801514","volume":"292","author":"J Zhao","year":"2017","unstructured":"Zhao J, Nussinov R, Ma B (2017) Mechanisms of recognition of amyloid- \u03b2 (A\u03b2) monomer, oligomer, and fibril by homologous antibodies. J Biol Chem 292:18325\u201318343","journal-title":"J Biol Chem"},{"key":"741_CR303","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00702-014-1180-8","volume":"121","author":"Y Zhou","year":"2014","unstructured":"Zhou Y, Danbolt NC (2014) Glutamate as a neurotransmitter in the healthy brain. J Neural Transm 121:799\u2013817","journal-title":"J Neural Transm"},{"key":"741_CR304","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1046\/j.1471-4159.2003.02273.x","volume":"88","author":"A Zourlidou","year":"2004","unstructured":"Zourlidou A, Payne-Smith MD, Latchman DS (2004) HSP27 but not HSP70 has a potent protective effect against alpha-synuclein-induced cell death in mammalian neuronal cells. J Neurochem 88:1439\u2013144810","journal-title":"J Neurochem"}],"container-title":["Cellular and Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10571-019-00741-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10571-019-00741-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10571-019-00741-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:21:48Z","timestamp":1664583708000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10571-019-00741-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,4]]},"references-count":294,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["741"],"URL":"https:\/\/doi.org\/10.1007\/s10571-019-00741-0","relation":{},"ISSN":["0272-4340","1573-6830"],"issn-type":[{"value":"0272-4340","type":"print"},{"value":"1573-6830","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,4]]},"assertion":[{"value":"13 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Authors declare that there are no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}